

chain nodes :

2 3 4 5 6 7 8 9 10 11 12 13 14 15 18 19

ring/chain nodes :

1
chain bonds :
1-2 2-3 3-4 4-5 4-19 5-6 5-15 6-7 7-8 7-18 8-9 8-14 9-10 10-11 10-13 11-12

exact/norm bonds :
1-2 4-19 5-6 5-15 6-7 8-14 10-11 10-13 11-12

exact bonds :
2-3 3-4 4-5 7-8 7-18 8-9 9-10

G1:C,H

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:Atom 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS

=> d his

(FILE 'HOME' ENTERED AT 11:22:01 ON 04 MAR 2003)

FILE 'REGISTRY' ENTERED AT 11:22:10 ON 04 MAR 2003

L1 STRUCTURE UPLOADED


L2 6 S L1

L3 132 S L1 FULL


=> d que 13 stat

L1 STR


C 21 H 22




Page 1-A



Page 1-B



Page 2-A



Page 3-A

VAR G1=21/22

REP G20=(0-2) 3-2 3-4

NODE ATTRIBUTES:

HCOUNT	IS M2	AT	3
HCOUNT	IS M1	AT	4
HCOUNT	IS M1	AT	6
HCOUNT	IS M1	AT	7
HCOUNT	IS M1	AT	8
HCOUNT	IS M2	AT	9
HCOUNT	IS M1	AT	14
NSPEC	IS RC	AT	1

NSPEC IS C AT 2
NSPEC IS C AT 3
NSPEC IS C AT 4
NSPEC IS C AT 5
NSPEC IS C AT 6
NSPEC IS C AT 7
NSPEC IS C AT 8
NSPEC IS C AT 9
NSPEC IS C AT 10
NSPEC IS C AT 11
NSPEC IS C AT 12
NSPEC IS C AT 13
NSPEC IS C AT 14
NSPEC IS C AT 15
NSPEC IS C AT 16
NSPEC IS C AT 17
NSPEC IS C AT 18
NSPEC IS C AT 19
NSPEC IS C AT 20
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 1 2 3 4 5 6 7 8 9 10 11 13 14 15 17 19 20
21 22
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L3 132 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 194 ITERATIONS 132 ANSWERS
SEARCH TIME: 00.00.01

=> fil capl
FILE 'CAPLUS' ENTERED AT 11:23:39 ON 04 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2003 VOL 138 ISS 10
FILE LAST UPDATED: 3 Mar 2003 (20030303/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

'FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s 13

L4 18 L3



=> d 1-18 ibib iabs hitstr

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2003-05780 CAPLUS
 DOCUMENT NUMBER: 134-86548
 TITLE: Preparation of heterocyclic(carbonyl) amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
 INVENTORS: Grömm, Daniel P., De Encarnação, Gary A., Fredas, John M.; Varsnet, Michael L.; Sikorski, James A.; Devasas, Balakrishnan; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.
 PATENT ASSIGNEES: G. D. Searle & Co., USA
 SOURCE: U.S., 85 pp., Cont.-In part of U. S. Ser. No. 402,419, abandoned
 CODEN: US000H
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE	
US 6172320	B1	200101109	US 1998-094994	19980403
WD 9628465	A1	19960919	MD 1996-052683	19960307
W, AL, AM, AT, AU, AZ, BG, BG, BT, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LA, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, CA, EE, ET, IL, IN, KE, KG, KP, KR, KZ, LA, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
PRIORITY APPL. INFO:		US 1995-080819	MD 19950310	
		WD 1996-022883	W 19960307	
		US 1995-074117	A2 19950407	

OTHER SOURCE(S): NAPPAT 134-86548
 GRAPHIC IMAGE:

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




ABSTRACT.
 Heterocyclic(carbonyl) amino acids, such as 1 (R1 = alkyl, alkyl, alkenyl, alkynyl, etc.; R2 = alkyl, arylalkyl, arylalkyl, arylalkyl, etc.; R3 = alkyl, cycloalkyl, R4 = aryl, heteroceryl; R5 = H, alkyl, nitrogen protecting group, etc. (= CH2 bond), were prep. for pharmaceutical use as HIV protease inhibitors for inhibiting retroviral processes, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection. Thus, II was prep. by a multistep synthetic sequence starting from N-protected-L-phenylalanine, -L-isoleucine, -L-proline, isobutylamine, and 3,3-benzodioxole. The prep. heterocyclic(carbonyl) amino acids were tested via an HIV inhibition assay.

IT 183563-92 6P
 RL: BAC (Biological activity) or effector, except adhesion; BSA (Biological study, unclassified); SPH (Synthetic preparation); THU (Therapeutic use); BTD (Biological study); PREP (Preparation); USES (Uses)
 (Group of heterocyclic(carbonyl) amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors)
 RN 183563-92-6 CAPLUS
 CH Propanamide, 2-amino N-((1S,2R)-3-((1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-phenylethyl)propyl-3-methylsulfonyl-1-methylpiperidine, (2R)-(2R) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



●HC1

IT 183563-90-4P 183563-91-6P
 RL: RCT (Reactant); SPH (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Group of heterocyclic(carbonyl) amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors)
 RN 183563-90-4 CAPLUS
 CH Carboxylic acid, ((1R)-2-((1S,2R)-3-((1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-phenylethyl)propyl)amino)-1-((methylsulfonyl)methyl)-2-oxoethyl)-, 1,1-dimethylethyl ester (XCI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183563-91-6 CAPLUS
 CH Carboxylic acid, ((1R)-2-((1S,2R)-3-((1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-phenylethyl)propyl)amino)-1-((methylsulfonyl)methyl)-2-oxoethyl)-, 1,1-dimethylethyl ester (XCI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)
 methylsulfonyl-2-hydroxy-1-(phenylethylsulfonyl)-2-
 [(chloromethyl)amino]-3-(methylsulfonyl)- (C01 - C02) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT. 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2003-789189 CAPLUS
 DOCUMENT NUMBER: 133-322130

TITLE: Synthesis of benzo-fused heterocyclic sulfonamide chlorides for preparation of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors
 INVENTORS: Kanda, Seisui A.; Latsenko, Leo J.; De Crescenzo, Gary A.
 PATENT ASSIGNEES: C. D. Seisui & Co., USA
 U.S. 95 pp., Cont. -in-part of U.S. 6,756,533.
 COUNTRY: USA:USA
 LANGUAGE: English
 FAMILY ACC. NUM. CONT. 5
 PATENT INFORMATION: 5

PATENT NO.	CLASS. DATE	APPLICATION NO.	DATE
US 6149056	A	20001181	US 1998-80079 19980519
US 5756533	A	19980526	US 1995-47052 19950107
EP 1258911	A1	20021120	EP 2002-11526 19960307
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI			
WO 99/99980	A1	19991125	WO 1999-45747 19991018
W: AE, AL, AM, AR, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, HU, IL, IN, IT, JP, KE, KG, KP, KR, KZ, LC, LI, LU, LT, LV, LY, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, VE, VN, YU, ZA, ZW, AS, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW, OM, OM, KE, LS, MW, SD, SI, SZ, US, ZH, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, SE, IT, LI, LU, MC, NL, PT, SE, SF, SK, CZ, CH, CA, CN, GW, HK, HR, ME, MN, TD, TG			
AU 799289A	A1	19981226	AU 1999-38684 19990518
US 6315080	B1	20011030	US 1999-451920 19991101
US 2002111368	A1	20020815	US 2001-836443 20010416
US 1468780	B2	20020815	

PRIORITY APPL. INFO :

US 1995-402287	B2	19950310
US 1995-47052	A2	19950507
EP 1994-907135	A3	19960307
US 1998-80238	A1	19980519
WO 1999-45747	A	19990518
US 1999-451920	A3	19991101

OTHER SOURCES:

CASREACT 133-322130; MMAPAT 133-322130

ABSTRACT:

Benzo-fused heterocyclic sulfonamide chlorides for the prep. of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors were obtained by a

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)
 process comprising reacting a benzo-fused heterocyclic compd. with an SO2 complex in the presence of a water miscible, non-reactive solvent at 0-75 degree, cooling, if necessary, to a temp. of from about -25 degree to about 45 degree, and then adding an alkyl halide. Thus, N-(2-hydroxy-2-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylsulfonyl)amino)-15-(phenylethylsulfonyl)-25-(pyrrolidin-1-yl)sulfonyl-2-3-dimethylbutanamide was prep. and shown to be an effective HIV protease inhibitor (ESD = 3 m, ES50 = 7 nM)


IT 183553-50-IP

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BUD (Biological study); PREP (Preparation); RACT (Reactant or reagent); UES (Uses)
 (Synthesis of benzo-fused heterocyclic sulfonamide chlorides for prep. of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors)

RN 183553-50-2 CAPLUS

N: 1-pyrrolidin-2-ylacetamide, N-[(R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylsulfonyl)amino)-2-hydroxy-1-(phenylethylsulfonyl)amino]-1-(methylsulfonyl)ethyl]-2-oxyethyl)- (C01) (CA INDEX NAME)

Absolute stereochemistry.



IT 183553-89-IP 183553-89-AP 183553-91-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Synthesis of benzo-fused heterocyclic sulfonamide chlorides for prep. of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors)

RN 183553-89-1 CAPLUS

N: 1-pyrrolidin-2-ylacetamide, N-[(R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylsulfonyl)amino)-2-hydroxy-1-(phenylethylsulfonyl)amino]-1-(methylsulfonyl)ethyl]-2-oxyethyl)-, monohydrochloride (C01) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 183553-90-4 CAPLUS

C: Carbanic acid, [(R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylsulfonyl)amino)-2-hydroxy-1-(phenylethylsulfonyl)amino]-1-(methylsulfonyl)ethyl]-2-oxyethyl)-, 1,1-dimethyl-ethyl ester (C01) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-91-5 CAPLUS

C: Carbanic acid, [(R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylsulfonyl)amino)-2-hydroxy-1-(phenylethylsulfonyl)amino]-1-(methylsulfonyl)ethyl]-2-oxyethyl)-, 1,1-dimethyl-ethyl ester (C01) (CA INDEX NAME)

Absolute stereochemistry




RN 183553-92-6 CAPLUS

C: Propanamide, 2-amino-N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylsulfonyl)amino)-2-hydroxy-1-(phenylethylsulfonyl)-3-methylsulfonyl)-

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)
monohydrochloride. (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry




● HCV

RN 183553-93-7 CAPLUS

Proprietary Name: N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(chloroacetyl)amino]-3-(methylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:753229 CAPLUS

TITLE:

for the preparation of amino acids as HIV protease inhibitors.

INVENTOR(S): Kunda, Sas

© 2006 Blackwell Publishing Ltd, *Journal of Internal Medicine* 260: 105–112

PATENT ASSIGNEE(S):
SOURCE:

NOTE:


DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT
DATE TIME LOCATION[illegible]

OTHER SOURCE(S): HARPAT 132:6692
GRAPHIC IMAGE:

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



ABSTRACT

[illegible]

1T 183553-89-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzo fused heterocycle sulfonyl) halide intermediates for the prepn. of amino acids as HIV protease inhibitors)

13953-89-1 CAPUS
1-Supplidinoxanthin

1-[[[1-(1-phenyl-1-propenyl)-2-methyl-2-propenyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-[[[methylsulfonyl)methyl]-2-oxoethyl]-, monohydrochloride (9C) (CA INDEX NAME)

Absolute stereochemistry




L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2013 ACS (Continued)

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAGT (Reactant or reagent)
(benzo fused heterocyclic sulfonyl halide intermediates for the prepn. of amino acids as HIV protease inhibitors)

PN 183553-90-4 CAPLUS

CN Carbamic acid, {[(1R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-[(methylthio)methyl]-2-oxoethyl]-, 1,1-dimethylethyl} (SC1) (CA INDEX NAME)


Absolute stereochemistry



RN 183563-91-5 CAPLUS

CM Carbamic acid, [(R)-2-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-1-[(methylsulfonyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry




RN 183553-92-6 CAPLUS

Propazamide, 2-amino-N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-(methylsulfonyl)-monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

17 183553-90-4P 183553-91-5P 183553-92-6P
183553-93-7P 183812-50-2P


L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.



RN 183004-74-2 CAPLUS

(C) Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(R)-nethylsulfonyl], (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RM 183054-78-6 CAPLUS

Propanamide, N-[(1S,2R)-3-[(5-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RN 18318.2-29-8 CAPLUS

Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-nethylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(S)-nethylsulfinyl]-, (2S)- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 183004-75-3P 183004-76-4P 183004-77-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of sulfonylalkenylamino hydroxyethylamino sulfonamide
retroviral protease inhibitors)

RN 183004-75-3 CAPLUS

Proprafenide, N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RW 183004-76-4 CAPLUS

Carbanic acid, [5-[[[(2R,3S)-2-hydroxy-3-[(2S)-2-methyl-3-(methylsulfonyl)-1-oxopropyl]amino]-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (SC1)
(CA INDEX NAME)

Absolute stereochemistry




RN 183004-77-5 CAPLUS

Propanamide, N-[[[(1S,2R)-3-[[[(2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.




[T 183004-99.] P 183005-01-89

RL, RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(presn. of sulfonfylalkanylamino hydroxyethylamino sulfonamide retroviral protease inhibitors)

RN 183004-99-1 CAPLUS

CH Ethanethioic acid, S-[(2S)-3-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry



IN 18305-01-B CAP115

CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylthio)-, (2S)-, (9CI) (CA INDEX NAME)


Absolute stereochemistry

REFERENCE COUNT

REFERENCE COUNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996-471499 CAPLUS

DOCUMENT NUMBER: 129122867

TITLE: Heterocyclic carbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
 INVENTOR(S): Gesman, Daniel P.; DeCrescenzo, Gary A.; Frenkel, Jason H.; Vazquez, Michael L.; Sliemers, James A.; Devadas, Balakrishnan; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.
 SOURCE: E.O. Searle & Co., USA
 U.S. 75 pp., Cont.-in-part of U. S. Ser. No. 402,419, abandoned.
 CODE: USXXM

PATENT ASSIGNEE(S):
 SOURCE: E.O. Searle & Co., USA
 U.S. 75 pp., Cont.-in-part of U. S. Ser. No. 402,419, abandoned.
 CODE: USXXM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5776971	A	19980707	US 1995-474117	19950607
CA 2218222	AA	19980619	CA 1995-2212022	19960307
WO 9628465	A1	19960619	WO 1995-050485	19960307
W. AL, AM, AT, AU, AZ, BB, BE, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KT, KG, KP, KR, KZ, LC, LI, LS, LT, LU, LV, MD, MG, MK, MN, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW, RU, US, VM, SD, SZ, US, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA				
AU 9554773	A1	19961002	AU 1996-54178	19960307
AU 717588	B2	20000230	EP 1996-911230	19960307
EP 815124	A1	19980107		
EP 815124	B1	20021204		
R, AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CA 1183302	A	19950527	CA 1996-18019	19960307
JP 11501929	T2	19990216	JP 1996-5297467	19960307
BR 9607625	A	19990615	BR 1996-7425	19960307
RU 2174519	C2	20011210	RU 1997-114529	19960307
AT 229033	E	20021215	AT 1996-911230	19960307
PL 184773	B1	20021231	PL 1996-302179	19960307
NO 9704147	A	19971104	NO 1997-4147	19970909
US 5972969	A	19991026	US 1996-28272	19950224
US 6843795	A	20030516	US 1999-307711	19990516
US 6714861	B1	20010410	US 2000-501266	20000909
US 6407124	B1	20020618	US 2001-775686	20010705
PRIORITY APPL. INFO:				
			US 1995-402419	B2 19950310
			US 1995-282335	B2 19950410
			US 1995-474117	A 19950607

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

ACCESSION NUMBER: 1996-471499 CAPLUS

DOCUMENT NUMBER: 129122867

TITLES: Heterocyclic carbonyl amino acid hydroxyethylamino sulfonamide derivatives

INVENTOR(S): Gesman, Daniel P.; DeCrescenzo, Gary A.; Frenkel, Jason H.; Vazquez, Michael L.; Sliemers, James A.; Devadas, Balakrishnan; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.

SOURCE: E.O. Searle & Co., USA

U.S. 75 pp., Cont.-in-part of U. S. Ser. No. 402,419, abandoned.

CODE: USXXM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

US 5776971

A

19980707

US 1995-474117

19950607

CA 2218222

AA

19980619

CA 1995-2212022

19960307

WO 9628465

A1

19960619

WO 1995-050485

19960307

W. AL, AM, AT, AU, AZ, BB, BE, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KT, KG, KP, KR, KZ, LC, LI, LS, LT, LU, LV, MD, MG, MK, MN, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

ACCESSION NUMBER: 1996-471499 CAPLUS

DOCUMENT NUMBER: 129122867

TITLES: Heterocyclic carbonyl amino acid hydroxyethylamino sulfonamide derivatives

INVENTOR(S): Gesman, Daniel P.; DeCrescenzo, Gary A.; Frenkel, Jason H.; Vazquez, Michael L.; Sliemers, James A.; Devadas, Balakrishnan; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.

SOURCE: E.O. Searle & Co., USA

U.S. 75 pp., Cont.-in-part of U. S. Ser. No. 402,419, abandoned.

CODE: USXXM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

US 5776971

A

19980707

US 1995-474117

19950607

CA 2218222

AA

19980619

CA 1995-2212022

19960307

WO 9628465

A1

19960619

WO 1995-050485

19960307

W. AL, AM, AT, AU, AZ, BB, BE, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KT, KG, KP, KR, KZ, LC, LI, LS, LT, LU, LV, MD, MG, MK, MN, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

ACCESSION NUMBER: 1996-471499 CAPLUS

DOCUMENT NUMBER: 129122867

TITLES: Heterocyclic carbonyl amino acid hydroxyethylamino sulfonamide derivatives

INVENTOR(S): Gesman, Daniel P.; DeCrescenzo, Gary A.; Frenkel, Jason H.; Vazquez, Michael L.; Sliemers, James A.; Devadas, Balakrishnan; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.

SOURCE: E.O. Searle & Co., USA

U.S. 75 pp., Cont.-in-part of U. S. Ser. No. 402,419, abandoned.

CODE: USXXM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

US 5776971

A

19980707

US 1995-474117

19950607

CA 2218222

AA

19980619

CA 1995-2212022

19960307

WO 9628465

A1

19960619

WO 1995-050485

19960307

W. AL, AM, AT, AU, AZ, BB, BE, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KT, KG, KP, KR, KZ, LC, LI, LS, LT, LU, LV, MD, MG, MK, MN, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

ACCESSION NUMBER: 1996-471499 CAPLUS

DOCUMENT NUMBER: 129122867

TITLES: Heterocyclic carbonyl amino acid hydroxyethylamino sulfonamide derivatives

INVENTOR(S): Gesman, Daniel P.; DeCrescenzo, Gary A.; Frenkel, Jason H.; Vazquez, Michael L.; Sliemers, James A.; Devadas, Balakrishnan; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.

SOURCE: E.O. Searle & Co., USA

U.S. 75 pp., Cont.-in-part of U. S. Ser. No. 402,419, abandoned.

CODE: USXXM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

US 5776971

A

19980707

US 1995-474117

19950607

CA 2218222

AA

19980619

CA 1995-2212022

19960307

WO 9628465

A1

19960619

WO 1995-050485

19960307

W. AL, AM, AT, AU, AZ, BB, BE, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KT, KG, KP, KR, KZ, LC, LI, LS, LT, LU, LV, MD, MG, MK, MN, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

ACCESSION NUMBER: 1996-471499 CAPLUS

DOCUMENT NUMBER: 129122867

TITLES: Heterocyclic carbonyl amino acid hydroxyethylamino sulfonamide derivatives

INVENTOR(S): Gesman, Daniel P.; DeCrescenzo, Gary A.; Frenkel, Jason H.; Vazquez, Michael L.; Sliemers, James A.; Devadas, Balakrishnan; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.

SOURCE: E.O. Searle & Co., USA

U.S. 75 pp., Cont.-in-part of U. S. Ser. No. 402,419, abandoned.

CODE: USXXM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

US 5776971

A

19980707

US 1995-474117

19950607

CA 2218222

AA

19980619

CA 1995-2212022

19960307

WO 9628465

A1


19960619

WO 1995-050485

19960307

W. AL, AM, AT, AU, AZ, BB, BE, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KT, KG, KP, KR, KZ, LC, LI, LS, LT, LU, LV, MD, MG, MK, MN, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996 392091 CAPLUS
DOCUMENT NUMBER: 129-11411
TITLE: Preparation of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors
INVENTOR(S): Getman, Daniel P.; Decrescenzo, Gary A.; Frenkel, John M.; Kozlowski, Michael L.; Skolnik, James A.; Denval, Balabhadra; Nagarajan, Srinivasan; Brown, David L.; McDonald, Joseph J.
PATENT ASSIGNMENT(S): C.D. Searle & Co., USA
U.S. 93 pp., Cont.-in-part of U. S. Ser. No. 402,287, abandoned.
COKEY: 1052AM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
US 5756533	A	19980026	US 1995-474052 19950607
CA 2253043	AA	19980019	CA 1996-2253043 19960307
WO 9804943	A1	19980019	WO 1996-050384 19960307
W. AL, AM, AT, AU, AZ, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GR, HU, IL, JP, KE, KG, KP, KR, KZ, LA, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI			
RU, RE, LS, MW, SD, SZ, UZ, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BF, CF, CG, CI, CH, CA			
AU 9602024	A1	19960202	AU 1996-50204 19960307
AU 702626	B2	19990202	
EP 813242	A1	19971229	EP 1996-907125 19960307
EP 815452	B1	20020316	
R AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FY			
CN 1865499	A	19980011	CN 1996-190620 19960307
JP 200153746	T2	20010904	JP 1996-527466 19960307
AT 225213	E	20021115	AT 1996-907125 19960307
EP 1258491	A1	20021120	EP 2002-19526 19960307
R AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FY			
PL 384748	B1	20021231	PL 1996-329784 19960307
RU 975848	A	19971027	RU 1997-4146 19970909
US 5966201	A	19991012	US 1998-326897 19980303
US 6146556	A	20000121	US 1998-088708 19980519
US 6310080	B1	20010320	US 1999-451920 19991201
US 200211356	A1	20020815	US 2001-836443 20010416
US 646876	B2	20020301	

L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

PRIORITY APPL. INFO.:
US 1995-482281 A2 19950310
US 1995-474052 A 19950607
EP 1996-907125 A3 19960307
US 1995-052941 A 19960307
US 1998-809298 A1 19980519
US 1999-451920 A2 19991201
OTHER SOURCE(S): MARPAT 129-4111
GRAPHIC IMAGE:




ABSTRACT:
Amino acid hydroxyethylamine sulfonamide compounds 1 (X = OH or ClCH₂, R₁ = alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, iminoalkyl, thioalkyl, C₆H₄CH₂, C₆H₄CH₂CH₂, C₆H₄CH₂CH₂CH₂, C₆H₄CH₂CH₂CH₂CH₂ or their sulfone or sulfonamide deriv.; R₂ = alkyl, aralkyl, alkoxyalkyl, aralkoxyalkyl, cycloalkylalkyl; R₃ = alkyl, cycloalkyl, cycloalkylmethyl; R₄ = aryl, benzo fused heterocyclic or heterocyclic; R₅ = H, alkyl, hydroxyalkyl, alkoxyalkyl; R₆ = H, alkyl, hydroxyalkyl, alkoxyalkyl, benzyl, iminoalkyl, thioalkyl, C₆H₄CH₂, C₆H₄CH₂CH₂, C₆H₄CH₂CH₂CH₂ or their sulfone or sulfonamide deriv.; R₇ = H, hydroxyalkyl, alkoxyalkyl; R₈, R₉ = H, alkyl, 2-hydroxyalkyl, hydroxyalkyl, alkoxyalkyl; or R₇ and R₈ or R₈ and R₉ form a heterocyclic or benzene ring) are prepared as retroviral protease inhibitors. Thus, 25-[(pyrrolidin-1-yl)acetyl]amino-1-[(2S)-hydroxy-3-[(1R)-2-methylpropyl]-N-[(2S)-2-hydroxybutan-3-yl]sulfonyl]amino]-1-(phenylethyl)propyl]-2-methylpentanamide, prep. from N-[(2S)-2-hydroxybutan-3-yl]sulfonyl-2-hydroxy-4-phenylbutyl)-N-methylamino, tert-butyl bromoacetate, pyrrolidine, and 2,3-dihydrofuran, showed HIV protease inhibitory activity IC₅₀ = 2 nM.

IT 183553-99-AP 183553-99-AP
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SW (Synthetic preparation); THU (Therapeutic use); BIL (Biological study); PREP (Preparation); CES (Uses)
(prop. of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors)

RN 183553-99-1 CAPLUS
CH 1-Pyrrolidinesulfonamide, N-[(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-1-(2-methylsulfonylmethyl)-2-oxoethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 183512-50-2 CAPLUS
CH 1-Pyrrolidinesulfonamide, N-[(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-1-(2-methylsulfonylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 183553-99-AP 183553-99-AP 183553-99-AP
RN 183553-99-AP
RL: ACT (Reactant); SW (Synthetic preparation); PREP (Preparation); BAC (Reactant or reagent)
(prop. of amino acid hydroxyethylamine sulfonamide retroviral protease inhibitors)

RN 183553-99-4 CAPLUS
CH Carbanic acid, N-[(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-1-[(2-methylsulfonylmethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 191412-78-9 CAPLUS

CM Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-{(4-oxido-4-oxoprop-1-yl)ethyl)sulfonyl}-2-oxoethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-79-0 CAPLUS

CM Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-{(4-mercapto-1-yl)-2-oxoethyl)sulfonyl}-2-oxoethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191412-80-3 CAPLUS

CM Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-(1-oxaprop-1-yl)ethyl)sulfonyl]-, meso/diastereomer, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

oxopropyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-87-0 CAPLUS

CM Propanamide, 3-[(14-benzimidazol-2-ylmethyl)sulfonyl]-N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-88-1 CAPLUS

CM Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(5-chloro-2-methyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 191412-91-6 CAPLUS

CM Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-pyridyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




• HCl

RN 191412-81-4 CAPLUS

CM Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-(1-oxaprop-1-yl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-82-5 CAPLUS

CM Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-{(1,1-dioxido-4-thioxoprop-1-yl)-2-oxoethyl)sulfonyl}-2-oxoethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-83-6 CAPLUS

CM Butanoic acid, 4-[(2S)-3-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191412-92-7 CAPLUS

CM Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-3-[(3-hydroxy-2-(hydroxymethyl)propyl)sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-93-8 CAPLUS

CM 6-Bromofuran-2-methyl 5-[(2S)-3-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]sulfonyl]-5-oxo-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 191412-95-0 CAPLUS

CM Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-(1-oxaprop-1-yl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 191412-96-1 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191412-97-2 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(4-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-99-4 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(5-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 191413-03-3 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(5-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191413-04-4 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(5-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-05-5 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuran-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 191413-06-0 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuran-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191413-01-1 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-02-2 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 191413-05-6 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191413-07-7 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-08-8 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(5-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl-2-methyl-3-[[2-oxo-2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-09-9 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(2S)-benzothiazol-5-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(2E)-2-(4-pyridyl)ethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-10-2 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(2E)-2-(4-pyridyl)ethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-11-3 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-4-benzodioxin-6-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(1H-pyrazol-3-ylmethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-15-7 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(1H-pyrazol-3-ylmethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-16-8 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(2E)-2-phenylethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-17-9 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(2E)-2-phenylethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-12-4 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(1H-pyrazol-3-ylmethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-13-5 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(5-benzothiazol-5-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(1H-pyrazol-3-ylmethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-14-6 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(1H-pyrazol-3-ylmethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-18-0 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(2E)-2-phenylethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-19-1 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(2E)-2-phenylethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-20-4 CAPLUS

CA Propanamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl]sulfonyl]-2-methylpropyl-1-phenylethyl-3-[(1S)-thiazol-5-ylmethyl]sulfonyl]-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM Propanamide, N-[(1S,2R)-3-[(5-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(5-thiazolylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry



RN 191413-24-8 CAPLUS
CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(5-thiazolylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RX 191413-26-0 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[[[2-(3,4-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[[2-(2-pyridinyl)propyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN	191413-36-2	CAPLUS
CN	Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[[2-(3-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.



RN 191413-38-4 CAPLUS
 CM Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[2-(3-pyridinyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RM 191413-40-8 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[2-(3-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 191413-29-3 CAPLUS
 CN Propenamide, N-[[[1S, 2S]-3-[[6-(benzothiazolyl)sulfonyl]-2-methylpropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[[[2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry



FN	191413-31-7	CAPLUS
CN	Propandamide, N-[(1S,2R)-3-[(5-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[[2-(2-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)	


Absolute stereochemistry



RN 191413-34-0 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[[[2,3-dihydro-5-benzofuranyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[[[2-(2-pyridinyl)ethyl]sulfonyl]-, (2S), (9CI) (CA INDEX NAME)


Absolute stereochemistry

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




191413-43-1 CAPLUS
Propanamide, N-[(1S,2R)-3-[(5-benzothiazolyl)sulfonyl]-2-methylpropyl]amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[[2-(3-pyridinyl)ethyl]sulfonyl]-, (2S), (2S) (CA INDEX NAME)

Absolute stereochemistry



(H) 191413-45-3 CAPLUS
 (H) Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[[[2-(3-pyridinyl)ethyl)sulfonyl]-, (2S), (9CI) (CA INDEX NAME)


Absolute stereochemistry



191413-47-5 CAPLUS
Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[[2-(4-pyridinyl)ethyl]sulfonyl]-, (2S), (2S), (9CI) (CA INDEX NAME)

Absolute stereochemistry


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-49-7 CAPLUS

Ch Propanamide, N-[(15,20)-3-[(12,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2,4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-50-0 CAPLUS

Ch Propanamide, N-[(15,20)-3-[(16-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2,4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-51-1 CAPLUS

Ch Propanamide, N-[(15,20)-3-[(16-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2,4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-58-8 CAPLUS

Ch 1-Pyrrolidinemethanecarboxylic acid, 2-[[[(2S)-3-[(15,20)-3-[(16-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]sulfonyl]methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-61-3 CAPLUS

Ch 1-Pyrrolidinemethanecarboxylic acid, 2-[[[(2S)-3-[(15,20)-3-[(12,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino)-2-methyl-3-oxopropyl]sulfonyl]methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-62-4 CAPLUS

Ch Propanamide, N-[(15,20)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2,4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-53-3 CAPLUS

Ch Propanamide, N-[(15,20)-3-[(12,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2,4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-56-6 CAPLUS

Ch 1-Pyrrolidinemethanecarboxylic acid, 2-[[[(2S)-3-[(15,20)-3-[(12,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]amino)-2-methyl-3-oxopropyl]sulfonyl]methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-57-7 CAPLUS

Ch 1-Pyrrolidinemethanecarboxylic acid, 2-[[[(2S)-3-[(15,20)-3-[(16-benzothiazolylsulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]amino)-2-methyl-3-oxopropyl]sulfonyl]methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-64-6 CAPLUS

Ch Propanamide, N-[(15,20)-3-[(12,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2,4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-65-7 CAPLUS

Ch Propanamide, N-[(15,20)-3-[(16-benzothiazolylsulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2,4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-66-8 CAPLUS

Ch Propanamide, N-[(15,20)-3-[(16-benzothiazolylsulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2,4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-67-9 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[[3-oxo-3-(1-propanoyl)propyl]sulfonyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-68-0 CAPLUS

CN Propanamide, 3-[[[(1S,2R)-3-[[[(2-aminoethyl)amino]-3-oxopropyl]sulfonyl]-N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 191413-69-1 CAPLUS

CN Propanamide, 3-[[[(2S)-[(2-aminoethyl)amino]-3-oxopropyl]sulfonyl]-N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-73-7 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[[3-hydroxy-2-(hydroxymethyl)propyl]sulfonyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 191413-75-9 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[[3-hydroxy-2-(hydroxymethyl)propyl]sulfonyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 191413-77-1 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[[3-hydroxy-2-(hydroxymethyl)propyl]sulfonyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-70-4 CAPLUS

CN Propanamide, 3-[[[(2S)-[(2-aminoethyl)amino]-3-oxopropyl]sulfonyl]-N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 191413-71-5 CAPLUS

CN Propanamide, 3-[[[(2S)-[(2-aminoethyl)amino]-3-oxopropyl]sulfonyl]-N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 191413-72-6 CAPLUS

CN Propanamide, 3-[[[(2S)-[(2-aminoethyl)amino]-3-oxopropyl]sulfonyl]-N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-79-3 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[[3-hydroxy-2-(hydroxymethyl)propyl]sulfonyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 191413-82-8 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[[3-hydroxy-2-(hydroxymethyl)propyl]sulfonyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 191413-84-0 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[[3-hydroxy-2-(hydroxymethyl)propyl]sulfonyl]-2-methyl-, (2S)-, (9CI) (CA INDEX NAME)]

Absolute stereochemistry.

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

CRN 76-05-1
 CMF C2 H F3 O2




RN 207686-83-7 CAPLUS

CR Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2S)-2-pyrrolidinylmethyl]sulfonyl]-, (2S)-, mono(trifluoroacetate) (salt) (SC1) (CA INDEX NAME)

CM 1

CRN 191412-90-5
 CMF C30 H43 N3 O8 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 207686-84-8 CAPLUS

CR Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino)-2-methyl-3-oxopropyl ester (SC1) (CA INDEX NAME)


Absolute stereochemistry.



RN 183005-01-8 CAPLUS

CR Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino)-2-methyl-3-(methylethyl)-, (2S)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-94-4 CAPLUS

CR 1-Pyrrolidinemethanesulfonic acid, 4-[[[(2S)-3-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino)-2-methyl-3-oxopropyl]thio]-1-oxopropyl]-, 1,1-dimethylethyl ester (SC1) (CA INDEX NAME)

Absolute stereochemistry.



RN 191412-97-0 CAPLUS

CR Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2R)-2-pyrrolidinylmethyl]thio]-, (2S)-, (SC1) (CA INDEX NAME)


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2S)-2-pyrrolidinylmethyl]sulfonyl]-, (2S)-, mono(trifluoroacetate) (salt) (SC1) (CA INDEX NAME)

CM 1

CRN 191412-89-2
 CMF C30 H43 N3 O8 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2



IT 183004-99-1P 183005-01-8P 191412-94-4P

191412-92-0P 191412-96-2P 191412-98-6P

191414-04-7P 191414-08-8P 191414-07-0P

191414-09-2P 191414-10-5P 191414-11-6P

191414-12-2P 191414-13-8P 191414-10-0P

191414-18-3P 191414-21-8P 191414-24-1P

191414-26-3P 191414-27-4P 191414-28-5P

191486-19-8P 191486-20-1P 207686-74-6P

207686-75-7P


RL: RCT (Reactant); SM (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Group of sulfonalkylamino hydroxyethylamino sulfonamide
 retinoid proteinase inhibitors)

RN 183004-99-1 CAPLUS

CR Lithanethioic acid, 5-[(2S)-3-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry.



RN 191412-94-2 CAPLUS

CR Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2R)-2-pyrrolidinylmethyl]thio]-1-oxopropyl]-, (2S)-, (SC1) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-98-6 CAPLUS

CR 1-Piperazinecarboxylic acid, 4-[[[(2S)-3-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino)-2-methyl-3-oxopropyl]thio]-1-oxopropyl]-, 1,1-dimethylethyl ester (SC1) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A




RN 191414-04-7 CAPLUS
 ON Propanamide, N-[(1S,2R)-3-[[1,3-benzodioxol-5-ylsulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethynyl)propyl]-2-methyl-3-[[2-(4-morpholinyl)-2-oxoethyl]thio]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry



RN 191414-05-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(2S)-3-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2-methyl-3-oxopropyl]thio]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.




RXN 191414-11-6 CAPLUS
 OR Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(1H-pyrazol-4-yl)methyl]thio]-, (2S)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.



RX 191414-12-7 CAPLUS
 CN Propanamide, 3-[(1H-benzimidazol-2-ylmethyl)thio]-N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-nethylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-nethyl-, (2S), (9C) (CA INDEX NAME)

Absolute stereochemistry.



RN 19144-13-8 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(5-thiazolylmethyl)thio]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPUS COPYRIGHT 2003 ACS (Cont Inued)

PAGE 1-8




RN 191414-07-0 CAPLUS
 CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-phenylethyl)thio]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry



RN 191414-09-2 CAPLUS
 CN Propenamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[(1H-imidazol-4-ylmethyl)thio]-2-methyl-, (2S)- (SC1) (CA INDEX NAME)


Absolute stereochemistry



PN 191414-1D-5 CAPLUS
 CN Propinamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-nethylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-nethyl-3-[(1H-pyrazol-3-ylmethyl)thio]-, (2S)- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

Q4 ANSWER 11 OF 18 CAP




RN 191414-15-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[(2S)-3-[[[(1S,2R)-3-[[1,3-benzodioxol-5-ylsulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2-methyl-3-oxopropyl]thio]methyl]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry



RN 1914-18-3 CAPUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[(2S)-3-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]thio]methyl]-, phenylmethyl ester, (2R), (9C1) (CA INDEX NAME)


Absolute stereochemistry.



1-Pyrrolidinecarboxylic acid, 2-[[[(2S)-3-[[[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]amino]-2-methyl-3-oxopropyl]sulfonyl]methyl]-, phenylmethyl ester, (2R)- (9C)
(CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191414-24-1 CAPLUS

CA Propanamide, N-((1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl)-2-methyl-3-((2-phenylethylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191414-26-3 CAPLUS


CA 3-Ribofuranoside, methyl 5-5'-(2S)-3-((1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl)amino)-2-methyl-3-oxopropyl)-2,3-O-(1-methylethylidene)-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191414-19-8 CAPLUS

CA Propanamide, N-((1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl)-2-methyl-3-((2-phenylethylthio)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191414-20-1 CAPLUS

CA Propanamide, N-((1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl)-2-methyl-3-((2-phenylethylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207606-74-6 CAPLUS

CA Propanamide, N-((1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl)-2-methyl-3-((2-((4-morpholinyl)ethyl)amino)-2-oxoethylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-B




RN 191414-27-4 CAPLUS

CA 3-Ribofuranoside, methyl 5-5'-(2S)-3-((1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl)amino)-2-methyl-3-oxopropyl)sulfonyl)-5-oxo-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 191414-28-5 CAPLUS

CA Propanamide, N-((1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl)-2-methyl-3-((2-phenylethylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 207606-75-7 CAPLUS

CA Propanamide, N-((1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl)-2-methyl-3-((2-oxo-2-(4-chlorophenyl)ethylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 174302-66-2P 183204-74-2P 183304-77-2P

183382-29-2P 191412-77-2P 191412-84-7P

191412-85-2P 191412-86-2P 191412-89-2P


191412-90-2P 191412-94-2P

RL SPN (Synthetic preparation); PREP (Preparation)
(prop. of sulfonamides) amino hydroxyethylamine sulfonamide
retroviral protease inhibitors

RN 174302-66-3 CAPLUS

CA Propanamide, N-((1S,2R)-3-((1,3-benzodioxol-5-yl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl)-2-methyl-3-((2-oxo-2-(4-chlorophenyl)ethylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 183004-74-2 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(R)-methylsulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183004-77-5 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[2-amino-6-benzothiazolyl]sulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-(methylethylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 183182-29-8 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(S)-methylsulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191412-86-9 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(1H-pyrazol-4-ylmethyl)thio]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-89-2 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[2R)-3-pyrrolidinylmethyl]thio]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191412-90-5 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[2R)-3-pyrrolidinylmethyl]thio]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 191412-77-8 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[3-oxo-3-(1-piperazinyl)propyl]thio]sulfonyl]-, monohydrate, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-84-7 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(1S)-indazol-4-ylmethyl]thio]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191412-89-8 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[1H-pyrazol-3-ylmethyl]thio]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191412-94-9 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[[[1,3-benzodioxol-5-ylsulfonyl]12-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[2-hydroxy-2,2-bis(hydroxymethyl)propyl]thio]sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE FORMAT

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)


181412-26-0P 181412-29-3P 181412-31-7P
 181412-34-0P 181412-36-2P 181412-38-4P
 181412-40-8P 181412-43-1P 181412-45-3P
 181412-47-5P 181412-49-7P 181412-50-9P
 181412-51-1P 181412-53-3P 181412-56-6P
 181412-57-7P 181412-58-8P 181412-61-3P
 181412-63-0P 181412-64-6P 181412-66-9P
 181412-68-8P 181412-67-9P 181412-68-0P
 181412-69-1P 181412-70-4P 181412-71-5P
 181412-72-6P 181412-73-7P 181412-75-9P
 181412-77-1P 181412-78-3P 181412-82-8P
 181412-84-0P 181412-86-2P 181412-88-4P

R_L (AC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BUS (Biological study); PRP (Preparation); ACS (Class)
 (propen. of N-(2-hydroxy-4-phenyl-3-(sulfonyl)amino)butyl)arylsulfonyl
 amides and analogs as retroviral protease inhibitors)

R_H 174303-66-3 CAPLUS

CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(1S-methylsulfonyl)-, (2S)- (SCL) (CA INDEX NAME)

Absolute stereochemistry

R_H 181004-77-5 CAPLUS


CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(1S-methylsulfonyl)-, (2S)- (SCL) (CA INDEX NAME)

Absolute stereochemistry




L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry

R_H 181412-76-7 CAPLUS


CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(2-[(1,4-oxido-1-glyoxalyl)ethyl]amino)-2-oxoethyl]sulfonyl]-, (2S)- (SCL) (CA INDEX NAME)

Absolute stereochemistry

R_H 181412-77-8 CAPLUS

CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(2-oxo-3-(1-piperazinyl)propyl)sulfonyl]-, monohydrochloride, (2S)- (SCL) (CA INDEX NAME)

Absolute stereochemistry




●(C)

R_H 181412-78-9 CAPLUS


CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(2-[(1,4-oxido-1-glyoxalyl)ethyl]amino)-2-oxoethyl]sulfonyl]-, (2S)- (SCL) (CA INDEX NAME)

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

R_H 181004-77-5 CAPLUS


CH Propanamide, N-[(1S,2R)-3-[(2-amino-6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(1S-methylsulfonyl)-, (2S)- (SCL) (CA INDEX NAME)

Absolute stereochemistry

R_H 181812-29-8 CAPLUS


CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(1S-methylsulfonyl)-, (2S)- (SCL) (CA INDEX NAME)

Absolute stereochemistry

R_H 181412-75-6 CAPLUS

CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(2-(2-pyridinyl)ethyl)sulfonyl]-, (2S)- (SCL) (CA INDEX NAME)


Absolute stereochemistry



L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)


(4-oxido-4-morpholinylethyl)amino)-2-oxoethyl]sulfonyl]-, (2S)- (SCL) (CA INDEX NAME)

Absolute stereochemistry

R_H 181412-79-0 CAPLUS


CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(2-(4-morpholinyl)-2-oxoethyl)sulfonyl]-, (2S)- (SCL) (CA INDEX NAME)

Absolute stereochemistry

R_H 181412-80-3 CAPLUS

CH Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(2-oxo-2-(1-piperazinyl)ethyl)sulfonyl]-, monohydrochloride, (2S)- (SCL) (CA INDEX NAME)

Absolute stereochemistry




●(C)

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 191412-81-4 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(2-oxo-2-phenylethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-82-5 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[(2-ethyl-4-chlorophenyl)sulfonyl]-2-oxoethyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-83-6 CAPLUS

ON Butanoic acid, 4-[(1S,2S)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-oxopropylthio-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

ON Propanamide, 3-[(1H-benzimidazol-2-yl)methyl)sulfonyl]-N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-86-1 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[(5-thiazolylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-89-2 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[(2S)-2-pyrrolyl(methyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191412-90-5 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[(1,2R)-2-pyrrolyl(methyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 191412-84-7 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[(1H-imidazol-4-ylmethyl)sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-85-8 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[(1H-pyrazol-3-yl)methyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-86-9 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(1H-pyrazol-4-yl)methyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191412-87-0 CAPLUS

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 191412-91-6 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-[(2-pyridinyl)methyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-92-7 CAPLUS

ON Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-[(2S)-2-hydroxyethyl)sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191412-93-8 CAPLUS

ON O-4-tetrafluoromethyl, methyl 5-[(2S)-3-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-oxopropyl]-3-oxo-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191412-94-9 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-95-0 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191412-96-1 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191412-01-1 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-02-2 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-03-3 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191412-97-2 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191412-99-4 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-00-0 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-04-4 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-05-5 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-06-6 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propan-1-yl 2-methyl-3-[(2-oxo-2-(2-pyridyl)ethyl)sulfonyl]-L-proline-1-Su (2S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-07-7 CAPLUS

CN Propanamide, N-[(15,20)-3-[(12,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-(4-pyridyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RN 191413-08-8 CAPLUS

CN Propanamide, N-[(15,20)-3-[(6-benzothiazolyl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-(4-pyridyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry




RN 191413-09-9 CAPLUS

CN Propanamide, N-[(15,20)-3-[(5-benzothiazolyl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-(4-pyridyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-13-5 CAPLUS

CN Propanamide, N-[(15,20)-3-[(5-benzothiazolyl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(1H-pyrazol-3-ylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RN 191413-14-6 CAPLUS

CN Propanamide, N-[(15,20)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(1H-pyrazol-3-ylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry




RN 191413-15-7 CAPLUS

CN Propanamide, N-[(15,20)-3-[(12,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-phenylethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-10-2 CAPLUS

CN Propanamide, N-[(15,20)-3-[(12,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-(4-pyridyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RN 191413-11-3 CAPLUS

CN Propanamide, N-[(15,20)-3-[(12,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(1H-pyrazol-3-ylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry




RN 191413-12-4 CAPLUS

CN Propanamide, N-[(15,20)-3-[(6-benzothiazolyl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(1H-pyrazol-3-ylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-16-8 CAPLUS

CN Propanamide, N-[(15,20)-3-[(6-benzothiazolyl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-phenylethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RN 191413-17-9 CAPLUS

CN Propanamide, N-[(15,20)-3-[(5-benzothiazolyl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-phenylethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry




RN 191413-18-0 CAPLUS

CN Propanamide, N-[(15,20)-3-[(12,3-dihydro-5-benzofuranyl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-oxo-2-phenylethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-19-1 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-acetyl-3-[(5-
thiazolylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-20-4 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(5-
thiazolylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-22-6 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(5-benzothiazol-5-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(5-
thiazolylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-31-7 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(5-benzothiazol-5-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-(2-
pyridinyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-34-0 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuran-5-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-(2-
pyridinyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-36-2 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-(2-
pyridinyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-24-8 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuran-6-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(5-
thiazolylmethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-26-9 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-(2-
pyridinyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-28-3 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-(2-
pyridinyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-38-4 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-(2-
pyridinyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-40-8 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(6-benzothiazol-5-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-(2-
pyridinyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-43-1 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(5-benzothiazol-5-yl)sulfonyl]-(2-
acetylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-(2-
pyridinyl)ethyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-46-3 CAPLUS

OR Propenamide, N-[(1S,2S)-3-[[[(2,3-dihydro-5-benzofuran-1-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[2-(4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-47-5 CAPLUS

OR Propenamide, N-[(1S,2S)-3-[[[(1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[2-(4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 191413-49-7 CAPLUS

OR Propenamide, N-[(1S,2S)-3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[2-(4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-56-6 CAPLUS

OR 1-Pyrrolidinedicarboxylic acid, 2-[[[(2S)-3-[[[(1S,2S)-3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]sulfonyl]methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-57-7 CAPLUS

OR 1-Pyrrolidinedicarboxylic acid, 2-[[[(2S)-3-[[[(1S,2S)-3-[[[(6-benzothiazol-1-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]sulfonyl]methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-58-8 CAPLUS

OR 1-Pyrrolidinedicarboxylic acid, 2-[[[(2S)-3-[[[(1S,2S)-3-[[[(6-benzothiazol-1-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]sulfonyl]methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-50-0 CAPLUS

OR Propenamide, N-[(1S,2S)-3-[[[(6-benzothiazol-1-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[2-(4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-51-1 CAPLUS

OR Propenamide, N-[(1S,2S)-3-[[[(6-benzothiazol-1-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[2-(4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-52-3 CAPLUS

OR Propenamide, N-[(1S,2S)-3-[[[(2,3-dihydro-5-benzofuran-1-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[2-(4-pyridinyl)ethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-61-3 CAPLUS

OR 1-Pyrrolidinedicarboxylic acid, 2-[[[(2S)-3-[[[(1S,2S)-3-[[[(2,3-dihydro-5-benzofuran-1-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]sulfonyl]methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-62-4 CAPLUS

OR Propenamide, N-[(1S,2S)-3-[[[(1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[3-oxo-3-(1-piperidinyl)propyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-64-6 CAPLUS

OR Propenamide, N-[(1S,2S)-3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[3-oxo-3-(1-piperidinyl)propyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-66-7 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-1-[(3-oxo-3-(1-phenylethyl)propyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-66-8 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-1-[(3-oxo-3-(1-phenylethyl)propyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-67-9 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-1-[(3-oxo-3-(1-phenylethyl)propyl)sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-71-5 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(2-aminoethyl)amino]-3-oxopropyl)sulfonyl]-N-[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-72-6 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(2-aminoethyl)amino]-3-oxopropyl)sulfonyl]-N-[(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-73-7 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(2,3-dihydro-6-benzofuranyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-68-0 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(2-aminoethyl)amino]-3-oxopropyl)sulfonyl]-N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-69-1 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(2-aminoethyl)amino]-3-oxopropyl)sulfonyl]-N-[(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-70-4 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(2-aminoethyl)amino]-3-oxopropyl)sulfonyl]-N-[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-75-9 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-3-[(3-hydroxy-2-(hydroxymethyl)propyl)sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-77-1 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(6-benzothiazolyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-3-[(3-hydroxy-2-(hydroxymethyl)propyl)sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191413-79-3 CAPLUS

OR Propenamide, N-[(1S,2R)-3-[(2,3-dihydro-5-benzofuranyl)sulfonyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-3-[(3-hydroxy-2-(hydroxymethyl)propyl)sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 191413-82-8 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2R)-2-pyrrolidinylmethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191413-84-0 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2R)-2-pyrrolidinylmethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry



RN 191413-86-2 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2R)-2-pyrrolidinylmethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 191413-91-8 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2R)-2-pyrrolidinylmethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191413-92-0 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2R)-2-pyrrolidinylmethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191413-94-2 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2R)-2-pyrrolidinylmethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191413-88-4 CAPLUS
 CN Propanamide, N-[(1S,2R)-3-[[[(2,3-dihydro-5-benzofuran-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[[[(2R)-2-pyrrolidinylmethyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 180064-09-1P 180065-01-8P 191413-92-2P
 191413-94-2P 191413-96-6P 191414-00-3P
 191414-02-5P 191414-04-7P 191414-05-9P
 191414-06-0P 191414-07-0P 191414-08-1P
 191414-09-2P 191414-10-5P 191414-11-6P
 191414-12-7P 191414-13-0P 191414-14-2P
 191414-18-3P 191414-21-9P 191414-24-1P
 191414-26-3P 191414-27-4P 191414-28-5P
 191460-19-8P 191460-20-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Group: of R-(2-hydroxy-4-phenyl-3-(sulfonyl)amino)butyl)aryl sulfonyl
 formulates and analogs as retroviral protease inhibitors)

RN 180064-09-1 CAPLUS
 CN Ethanedithioic acid, 5-[(2S)-3-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-oxopropyl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191412-98-6 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]amino]-2-oxopropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 191414-00-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(2S)-3-[[[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]amino]-2-oxopropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191414-12-7 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191414-13-8 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(5-thiazolylethyl)thio]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191414-15-0 CAPLUS

CN 1-Pyrrolidinedicarboxylic acid, 2-[[[(2S)-3-[[[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]thio)methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 191414-26-3 CAPLUS

CN D-Ribofuranoside, methyl 5'-[(2S)-3-[[[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]-2,3-d-(1-methylethylidene)-5-thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 191414-27-4 CAPLUS

CN D-Ribofuranoside, methyl 5'-[(2S)-3-[[[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]-2,3-d-(1-methylethylidene)-5-thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 191414-18-3 CAPLUS

CN 1-Pyrrolidinedicarboxylic acid, 2-[[[(2S)-3-[[[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]thio)methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191414-21-8 CAPLUS

CN 1-Pyrrolidinedicarboxylic acid, 2-[[[(2S)-3-[[[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-2-methyl-3-oxopropyl]thio)methyl]-, phenylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191414-24-1 CAPLUS


CN Propanamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-(2-pyridinylethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 1-B



RN 191414-28-5 CAPLUS

CN Propanamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-3-[[[3-hydroxy-2,2-bis(hydroxymethyl)propyl]thio]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191414-29-8 CAPLUS


CN Propanamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]-3-[[[3-(2-phenyl-1,3-dioxan-5-ylmethyl)thio]-, (5S)-[1S,2R]-3-epitriol]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 191486-29-1 CAPLUS
 CN Propanediol, 2-amino-3-[[1-(3-benzodioxol-5-ylsulfonyl)-2-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-phenyl-1,3-dioxan-5-yl)methyl]sulfonyl-, [E]-(S,S)-[C(1,3-20)]-(part-1)- (SC1) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999-8904 CAPLUS
 DOCUMENT NUMBER: US-5165

TITLE: Preparation of N-heterocycliccarbonyl amino acid hydroxyethylamino sulfonamide as retroviral protease inhibitors

INVENTOR(S): Gocman, Daniel P.; Decrescenzo, Gary A.; Freidus, John H.; Yacaman, Michael L.; Sikorski, Janet A.; Orendas, Ralewska; Nagarajan, Srinivasan; Brown, David L.; Kozminski, Joseph J.

PATENT ASSIGNEE(S): G.D. Searle & Co., USA
 SOURCE: PCT Int. Appl., 184 pp.
 CODES: P1002

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620465	A1	19960919	US 1996-052683	19960307
M. AL. AM. AT. AU. AZ. BB. BG. BR. BY. CA. CH. CN. CZ. DE. DK. EE. ES. FI. GB. GE. GR. HU. IL. JP. KE. KG. KP. KR. KZ. LA. LR. LS. LT. LU. LV. MD. MG. MK. MN. MW. MX. MY. NZ. PL. PT. RO. RU. SD. SE. SG. SI				
RW. SC. ES. MW. SD. SZ. US. AT. BE. CH. DE. DK. ES. FI. FR. GB. GR. SE. IT. LU. MC. NL. PT. SE. BF. BJ. CF. CG. CI. CN. GA. GU. HT. IL. IN. IS. KE. KG. KP. KR. KZ. LA. LR. LS. LT. LU. LV. MD. MG. MK. MN. MW. MX. MY. NZ. PL. PT. RO. RU. SD. SE. SG. SI				
RW. SC. ES. MW. SD. SZ. US. AT. BE. CH. DE. DK. ES. FI. FR. GB. GR. SE. IT. LU. MC. NL. PT. SE. BF. BJ. CF. CG. CI. CN. GA. GU. HT. IL. IN. IS. KE. KG. KP. KR. KZ. LA. LR. LS. LT. LU. LV. MD. MG. MK. MN. MW. MX. MY. NZ. PL. PT. RO. RU. SD. SE. SG. SI				
AU 9664178	A1	19961002	AU 1996-54178	19960307
AU 71598	RZ	20000330		
EP 85324	A1	19980107	EP 1996-511230	19960307
EP 85134	B1	20021204		
R. AT. BE. CH. DE. DK. ES. FR. GB. GR. IT. LI. LU. NL. SE. PT. IE. FI				
JP 11501920	TZ	19990216	JP 1996-527647	19960307
BR 9601625	A	19990615	BR 1996-7625	19960307
RU 7217619	C2	20011019	RU 1997-11625	19960307
AT 2002103	E	20021215	AT 1996-511230	19960307
RU 18471	B1	20021231	RU 1996-527647	19960307
MD 9704147	A	19971104	MD 1997-4147	19970909
US 6172101	B1	20011109	US 1996-89984	19960413
PRIORITY APPL. INFO:				
US 1996-602419	A2	19960310		
US 1996-674117	A2	19960607		
WO 1996-052683	M	19960307		

OTHER SOURCE(S): MARIAT 126-31657

GRAPHIC IMAGE:

L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



ABSTRACT:

Selected heterocycliccarbonyl amino acid hydroxyethylamino sulfonamide compounds of formula (I), (II) = C1-5 alkyl, C2-5 alkyl or alkaryl, C1-3 hydroxyalkyl, C1-3 alkyl, C1-3 alkyl, cyano-C1-3 alkyl, isobutoxymethyl, C2-C6OCH₂, C2-C6OCH₂, C2-C6OCH₂ (n = 0, 1, 2), C2-C6OCH₂ (n = 0, 1, 2); R2 = C1-5 alkyl, C1-3 alkyl, allylthio-C1-3 alkyl, arylthio-C1-3 alkyl, 3- to 6-membered heterocyclic-C1-3 alkyl; R4 = aryl, benzo-fused 5- to 6-membered heterocyclic or heterocyclic, etc.; R6 = H, C1-3 hydroxyalkyl, alkyl-C1-3 alkyl; R12, R13 = H, OH, H2C=CH₂, C1-3 hydroxyalkyl, alkyl-C1-3 alkyl; or R12 and R13 or R12 and R13 along with the C atoms to which they are attached represent a benzo radical optionally substituted with at least one H or C1-3 alkyl radical(s) are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease, and for the treatment of AIDS. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, compounds and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and the treatment of a retroviral infection. Thus, tert-butyl ester, (I); R = H (given) was condensed with 2-Pro-Gu using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and HOBt in DMF followed by hydrolysis and acidification with HCl to give proline compound, peptide analog 11 (ACT (R = H-pro)). The latter compound, in vitro showed IC50 of 1 nM for inhibiting the proliferation of HIV-1 in cell cells.

IT 183553-99-4P 183553-91-5P 183553-92-6P

R, RCT (Reactant); SN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent).


(Synthesis of N-heterocycliccarbonyl amino acid N-(hydroxyethylamino)disulfonyl amides as retroviral protease inhibitors for AIDS treatment)

RN 183553-91-5 CAPLUS

CN Carbanic acid, [(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-2-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-1-[(methoxycarbonyl)amino]-2-oxoethyl]-, 1,1-dimethyl ester (SC1) (CA INDEX NAME)

L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry.



RN 183553-91-5 CAPLUS

CN Carbanic acid, [(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)-2-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-1-[(methoxycarbonyl)amino]-2-oxoethyl]-, 1,1-dimethyl ester (SC1) (CA INDEX NAME)


Absolute stereochemistry.



RN 183553-92-6 CAPLUS


CN Propanediol, 2-amino-3-[[1-(3-benzodioxol-5-ylsulfonyl)-2-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-methyl-3-[(2-phenyl-1,3-dioxan-5-yl)methyl]sulfonyl-, [E]-(S,S)-[C(1,3-20)]-(part-1)- (SC1) (CA INDEX NAME)

Absolute stereochemistry.



● C1

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

OTHER SOURCE(S): US 1999-451930 A3 19991201
GRAPHIC IMAGE: MARPAT 126-15031

ABSTRACT:

Title compds. (1: n = 1, 2; R1 = alkyl, alkylenyl, alkynyl, hydroalkyl, alkoalkyl, cycloalkyl, imidazolylalkyl, CH2OH, CH2OH, etc.; R2 = alkyl, alkylenyl, alkoalkyl, arylalkyl, cycloalkylalkyl, R3 = alkyl, cycloalkyl, cycloalkylmethyl, R4 = aryl, heterocycloalkyl, R10 = H, alkyl, hydroalkyl, alkoalkyl, R11 = H, alkyl, hydroalkyl, alkoalkyl, R12 = H, hydroalkyl, alkoalkyl; R13, R14 = H, alkyl, 2-hydroxyethyl, hydroalkyl, alkoalkyl; R15, R16 = atoms to form 5-6 membered heterocycle or benzene ring), were prod'd. Thus, title comp'd. (1), prod'd. by soln. phase means, substituted HIV protease with IC50 = 2 nM.

IT 183553-90-EP 183553-90-EP

AL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SM (Synthetic preparation); THU (Therapeutic use); BIR (Biological study); REP (Preparation); USE (Use)

IN 183553-90-EP 183553-90-EP
CA: 1-Pyrrolidineacetamide, N-[(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)formyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-1-[(methylethyl)amino]-2-octenyl]-1-oxo-1,2-dihydro-1,2,4-benzodioxole-5-carboxamide (SC1) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996-10284 CAPLUS
DOCUMENT NUMBER: 136-15031

TITLE: Preparation of peptidic hydroxylaminosulfonamide analogs as retroviral protease inhibitors.
INVENTOR(S): Gelman, Daniel P.; Decrescenzo, Gary A.; Frenkel, John M.; Valquez, Michael L.; Sklar, James A.; Odeh, David L.; Salazar, Juan Carlos; Srinivasan, Brown, David L.; McDonald, Joseph J.

PATENT ASSIGNMENT(S): C.D. Swartz & Co., USA
SOURCE: PCT Int. Appl., 212 pp.

CODEN: PLUGS2

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 928443	A1	19920919	WO 1996-152684	19960307
W: AL, AM, AT, AU, AZ, BB, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GR, HU, IS, JP, KE, KG, KP, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MY, NZ, OC, PA, PT, RO, RU, SE, SG, SI, SK, SL, SM, SN, SV, TH, TJ, TR, TT, UA, UG, US, UZ, VC, VE, YU, ZA, ZW				
IN: EE, ES, HU, SG, SI, US, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, US 5755533 A 19980526 US 1995-474052 19960607				
AU 5602294 A1 19961027 AU 1996-56294 19960307				
AU 702260 B2 19990220				
EP 813542 A1 19971229 EP 1996-907135 19960307				
EP 813542 B1 20020116				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
BR 9607320 B 19980226 BR 1996-7638 19960307				
JP 200133746 T2 20010904 JP 1996-527648 19960307				
AT 226213 E 20021115 AT 1996-907135 19960307				
EP 1254951 A1 20021120 EP 2002-11226 19960307				
S: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
PL 184746 B1 20021231 PL 1996-327794 19960307				
MD 5704148 A 19971027 MD 1997-4148 19970909				
US 5946970 A 19991019 US 1998-894600 19980302				
US 200211386 A1 20020515 US 2001-836443 20010418				
US 6458785 B2 20021001 US 1996-482787 A2 19960310				
US 1995-474052 A2 19950607				
EP 1996-907135 A3 19960307				
MD 1996-022604 A 19960307				

PRIORITY APPL. INFO:


L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



IN 183553-90-2 CAPLUS

CA: 1-Pyrrolidineacetamide, N-[(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)formyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-1-[(methylethyl)amino]-2-octenyl]-1-oxo-1,2-dihydro-1,2,4-benzodioxole-5-carboxamide (SC1) (CA INDEX NAME)

Absolute stereochemistry.




IT 183553-90-EP 183553-91-EP 183553-92-EP

183553-93-79

AL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SM (Synthetic preparation); THU (Therapeutic use); BIR (Biological study); REP (Preparation); USE (Use)

IN 183553-90-4 CAPLUS
CA: Carbamic acid, [(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)formyl]-(2-methylpropyl)amino]-2-hydroxy-1-(phenylethyl)propyl]amino]-1-[(methylethyl)amino]-2-octenyl]-1-oxo-1,2-dihydro-1,2,4-benzodioxole-5-carboxamide (SC1) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 183563-91-5 CAPLUS

CR Carbanic acid, [(1R)-2-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)]2-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-[(methylethylsulfonyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (EC1) (CA INDEX NAME)


Absolute stereochemistry.



RN 183563-92-6 CAPLUS

CR Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)]2-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-[(methylethylsulfonyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (EC1) (CA INDEX NAME)

Absolute stereochemistry.



RN 183563-93-7 CAPLUS

CR Propanamide, N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)]2-methylpropyl]amino]-2-hydroxy-1-(phenylethyl)propyl]-2-[(methylethylsulfonyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (EC1) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996-732933 CAPLUS

DOCUMENT NUMBER: 126.8710

TITLE: Preparation of bisimino acid

hydroxyethylaminoaldehyde retroviral protease

inhibitors.

INVENTORS: Gröten, Daniel P.; Descombes, Gary A.; Frieslos, John M.; Vasquez, Michael L.; Sitarski, James A.; Ovalles, Roldando; Kapanjian, Srinivasan; Brown, David L.; McDonald, Joseph J.

PATENT ASSIGNEE(S): G.D. Searle & Co., USA

SOURCE: ACT 14, Appl., 255 p.

CODEN: P1002

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9628464	A1	19960919	MO 1996-052686	19960207
W	AL, AR, AT, AU, AZ, BE, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LA, LU, NL, NO, NZ, PL, PT, RU, SD, SE, SG, SI			
US 6195566	A	2001121	US 1995-479071	19950607
AU 965361	A1	19961002	AU 1996-53561	19960207
AU 705360	B2	19960422		
BR 9607543	A	19971223	BR 1996-7543	19960207
EP 812543	A1	19970229	EP 1996-910337	19960207
R	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, PT, IE, SI, LT, LV, FI			
JP 11601361	TE	19990216	JP 1996-527649	19960207
EP 1188766	A1	20020220	EP 2001-120219	19960207
R	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, PT, IE, SI, LT, LV, FI			
NO 9704149	A	19971105	NO 1997-4149	19970909
US 6163788	A	20011107	US 1996-910396	19960121
PRIORITY APPL. INFO:			US 1996-402450	A2 19950310
			US 1995-479071	A 19950607
			EP 1996-910337	A9 19960207
			MO 1996-052685	W 19960207


OTHER SOURCE(S): NABPAT 126.8710

GRAPHIC IMAGE:

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




ABSTRACT:

R1R2R3CH(R1)C(R2)C(R3)C(R4)C(R5)C(R6)C(R7)C(R8)C(R9)C(R10)C(R11)C(R12)C(R13)C(R14)C(R15)C(R16)C(R17)C(R18)C(R19)C(R20)C(R21)C(R22)C(R23)C(R24)C(R25)C(R26)C(R27)C(R28)C(R29)C(R30)C(R31)C(R32)C(R33)C(R34)C(R35)C(R36)C(R37)C(R38)C(R39)C(R40)C(R41)C(R42)C(R43)C(R44)C(R45)C(R46)C(R47)C(R48)C(R49)C(R50)C(R51)C(R52)C(R53)C(R54)C(R55)C(R56)C(R57)C(R58)C(R59)C(R60)C(R61)C(R62)C(R63)C(R64)C(R65)C(R66)C(R67)C(R68)C(R69)C(R70)C(R71)C(R72)C(R73)C(R74)C(R75)C(R76)C(R77)C(R78)C(R79)C(R80)C(R81)C(R82)C(R83)C(R84)C(R85)C(R86)C(R87)C(R88)C(R89)C(R90)C(R91)C(R92)C(R93)C(R94)C(R95)C(R96)C(R97)C(R98)C(R99)C(R100)C(R101)C(R102)C(R103)C(R104)C(R105)C(R106)C(R107)C(R108)C(R109)C(R110)C(R111)C(R112)C(R113)C(R114)C(R115)C(R116)C(R117)C(R118)C(R119)C(R120)C(R121)C(R122)C(R123)C(R124)C(R125)C(R126)C(R127)C(R128)C(R129)C(R130)C(R131)C(R132)C(R133)C(R134)C(R135)C(R136)C(R137)C(R138)C(R139)C(R140)C(R141)C(R142)C(R143)C(R144)C(R145)C(R146)C(R147)C(R148)C(R149)C(R150)C(R151)C(R152)C(R153)C(R154)C(R155)C(R156)C(R157)C(R158)C(R159)C(R160)C(R161)C(R162)C(R163)C(R164)C(R165)C(R166)C(R167)C(R168)C(R169)C(R170)C(R171)C(R172)C(R173)C(R174)C(R175)C(R176)C(R177)C(R178)C(R179)C(R180)C(R181)C(R182)C(R183)C(R184)C(R185)C(R186)C(R187)C(R188)C(R189)C(R190)C(R191)C(R192)C(R193)C(R194)C(R195)C(R196)C(R197)C(R198)C(R199)C(R200)C(R201)C(R202)C(R203)C(R204)C(R205)C(R206)C(R207)C(R208)C(R209)C(R210)C(R211)C(R212)C(R213)C(R214)C(R215)C(R216)C(R217)C(R218)C(R219)C(R220)C(R221)C(R222)C(R223)C(R224)C(R225)C(R226)C(R227)C(R228)C(R229)C(R230)C(R231)C(R232)C(R233)C(R234)C(R235)C(R236)C(R237)C(R238)C(R239)C(R240)C(R241)C(R242)C(R243)C(R244)C(R245)C(R246)C(R247)C(R248)C(R249)C(R250)C(R251)C(R252)C(R253)C(R254)C(R255)C(R256)C(R257)C(R258)C(R259)C(R260)C(R261)C(R262)C(R263)C(R264)C(R265)C(R266)C(R267)C(R268)C(R269)C(R270)C(R271)C(R272)C(R273)C(R274)C(R275)C(R276)C(R277)C(R278)C(R279)C(R280)C(R281)C(R282)C(R283)C(R284)C(R285)C(R286)C(R287)C(R288)C(R289)C(R290)C(R291)C(R292)C(R293)C(R294)C(R295)C(R296)C(R297)C(R298)C(R299)C(R300)C(R301)C(R302)C(R303)C(R304)C(R305)C(R306)C(R307)C(R308)C(R309)C(R310)C(R311)C(R312)C(R313)C(R314)C(R315)C(R316)C(R317)C(R318)C(R319)C(R320)C(R321)C(R322)C(R323)C(R324)C(R325)C(R326)C(R327)C(R328)C(R329)C(R330)C(R331)C(R332)C(R333)C(R334)C(R335)C(R336)C(R337)C(R338)C(R339)C(R340)C(R341)C(R342)C(R343)C(R344)C(R345)C(R346)C(R347)C(R348)C(R349)C(R350)C(R351)C(R352)C(R353)C(R354)C(R355)C(R356)C(R357)C(R358)C(R359)C(R360)C(R361)C(R362)C(R363)C(R364)C(R365)C(R366)C(R367)C(R368)C(R369)C(R370)C(R371)C(R372)C(R373)C(R374)C(R375)C(R376)C(R377)C(R378)C(R379)C(R380)C(R381)C(R382)C(R383)C(R384)C(R385)C(R386)C(R387)C(R388)C(R389)C(R390)C(R391)C(R392)C(R393)C(R394)C(R395)C(R396)C(R397)C(R398)C(R399)C(R400)C(R401)C(R402)C(R403)C(R404)C(R405)C(R406)C(R407)C(R408)C(R409)C(R410)C(R411)C(R412)C(R413)C(R414)C(R415)C(R416)C(R417)C(R418)C(R419)C(R420)C(R421)C(R422)C(R423)C(R424)C(R425)C(R426)C(R427)C(R428)C(R429)C(R430)C(R431)C(R432)C(R433)C(R434)C(R435)C(R436)C(R437)C(R438)C(R439)C(R440)C(R441)C(R442)C(R443)C(R444)C(R445)C(R446)C(R447)C(R448)C(R449)C(R450)C(R451)C(R452)C(R453)C(R454)C(R455)C(R456)C(R457)C(R458)C(R459)C(R460)C(R461)C(R462)C(R463)C(R464)C(R465)C(R466)C(R467)C(R468)C(R469)C(R470)C(R471)C(R472)C(R473)C(R474)C(R475)C(R476)C(R477)C(R478)C(R479)C(R480)C(R481)C(R482)C(R483)C(R484)C(R485)C(R486)C(R487)C(R488)C(R489)C(R490)C(R491)C(R492)C(R493)C(R494)C(R495)C(R496)C(R497)C(R498)C(R499)C(R500)C(R501)C(R502)C(R503)C(R504)C(R505)C(R506)C(R507)C(R508)C(R509)C(R510)C(R511)C(R512)C(R513)C(R514)C(R515)C(R516)C(R517)C(R518)C(R519)C(R520)C(R521)C(R522)C(R523)C(R524)C(R525)C(R526)C(R527)C(R528)C(R529)C(R530)C(R531)C(R532)C(R533)C(R534)C(R535)C(R536)C(R537)C(R538)C(R539)C(R540)C(R541)C(R542)C(R543)C(R544)C(R545)C(R546)C(R547)C(R548)C(R549)C(R550)C(R551)C(R552)C(R553)C(R554)C(R555)C(R556)C(R557)C(R558)C(R559)C(R560)C(R561)C(R562)C(R563)C(R564)C(R565)C(R566)C(R567)C(R568)C(R569)C(R570)C(R571)C(R572)C(R573)C(R574)C(R575)C(R576)C(R577)C(R578)C(R579)C(R580)C(R581)C(R582)C(R583)C(R584)C(R585)C(R586)C(R587)C(R588)C(R589)C(R590)C(R591)C(R592)C(R593)C(R594)C(R595)C(R596)C(R597)C(R598)C(R599)C(R600)C(R601)C(R602)C(R603)C(R604)C(R605)C(R606)C(R607)C(R608)C(R609)C(R610)C(R611)C(R612)C(R613)C(R614)C(R615)C(R616)C(R617)C(R618)C(R619)C(R620)C(R621)C(R622)C(R623)C(R624)C(R625)C(R626)C(R627)C(R628)C(R629)C(R630)C(R631)C(R632)C(R633)C(R634)C(R635)C(R636)C(R637)C(R638)C(R639)C(R640)C(R641)C(R642)C(R643)C(R644)C(R645)C(R646)C(R647)C(R648)C(R649)C(R650)C(R651)C(R652)C(R653)C(R654)C(R655)C(R656)C(R657)C(R658)C(R659)C(R660)C(R661)C(R662)C(R663)C(R664)C(R665)C(R666)C(R667)C(R668)C(R669)C(R670)C(R671)C(R672)C(R673)C(R674)C(R675)C(R676)C(R677)C(R678)C(R679)C(R680)C(R681)C(R682)C(R683)C(R684)C(R685)C(R686)C(R687)C(R688)C(R689)C(R690)C(R691)C(R692)C(R693)C(R694)C(R695)C(R696)C(R697)C(R698)C(R699)C(R700)C(R701)C(R702)C(R703)C(R704)C(R705)C(R706)C(R707)C(R708)C(R709)C(R710)C(R711)C(R712)C(R713)C(R714)C(R715)C(R716)C(R717)C(R718)C(R719)C(R720)C(R721)C(R722)C(R723)C(R724)C(R725)C(R726)C(R727)C(R728)C(R729)C(R730)C(R731)C(R732)C(R733)C(R734)C(R735)C(R736)C(R737)C(R738)C(R739)C(R740)C(R741)C(R742)C(R743)C(R744)C(R745)C(R746)C(R747)C(R748)C(R749)C(R750)C(R751)C(R752)C(R753)C(R754)C(R755)C(R756)C(R757)C(R758)C(R759)C(R760)C(R761)C(R762)C(R763)C(R764)C(R765)C(R766)C(R767)C(R768)C(R769)C(R770)C(R771)C(R772)C(R773)C(R774)C(R775)C(R776)C(R777)C(R778)C(R779)C(R780)C(R781)C(R782)C(R783)C(R784)C(R785)C(R786)C(R787)C(R788)C(R789)C(R790)C(R791)C(R792)C(R793)C(R794)C(R795)C(R796)C(R797)C(R798)C(R799)C(R800)C(R801)C(R802)C(R803)C(R804)C(R805)C(R806)C(R807)C(R808)C(R809)C(R810)C(R811)C(R812)C(R813)C(R814)C(R815)C(R816)C(R817)C(R818)C(R819)C(R820)C(R821)C(R822)C(R823)C(R824)C(R825)C(R826)C(R827)C(R828)C(R829)C(R830)C(R831)C(R832)C(R833)C(R834)C(R835)C(R836)C(R837)C(R838)C(R839)C(R840)C(R841)C(R842)C(R843)C(R844)C(R845)C(R846)C(R847)C(R848)C(R849)C(R850)C(R851)C(R852)C(R853)C(R854)C(R855)C(R856)C(R857)C(R858)C(R859)C(R860)C(R861)C(R862)C(R863)C(R864)C(R865)C(R866)C(R867)C(R868)C(R869)C(R870)C(R871)C(R872)C(R873)C(R874)C(R875)C(R876)C(R877)C(R878)C(R879)C(R880)C(R881)C(R882)C(R883)C(R884)C(R885)C(R886)C(R887)C(R888)C(R889)C(R890)C(R891)C(R892)C(R893)C(R894)C(R895)C(R896)C(R897)C(R898)C(R899)C(R900)C(R901)C(R902)C(R903)C(R904)C(R905)C(R906)C(R907)C(R908)C(R909)C(R910)C(R911)C(R912)C(R913)C(R914)C(R915)C(R916)C(R917)C(R918)C(R919)C(R920)C(R921)C(R922)C(R923)C(R924)C(R925)C(R926)C(R927)C(R928)C(R929)C(R930)C(R931)C(R932)C(R933)C(R934)C(R935)C(R936)C(R937)C(R938)C(R939)C(R940)C(R941)C(R942)C(R943)C(R944)C(R945)C(R946)C(R947)C(R948)C(R949)C(R950)C(R951)C(R952)C(R953)C(R954)C(R955)C(R956)C(R957)C(R958)C(R959)C(R960)C(R961)C(R962)C(R963)C(R964)C(R965)C(R966)C(R967)C(R968)C(R969)C(R970)C(R971)C(R972)C(R973)C(R974)C(R975)C(R976)C(R977)C(R978)C(R979)C(R980)C(R981)C(R982)C(R983)C(R984)C(R985)C(R986)C(R987)C(R988)C(R989)C(R990)C(R991)C(R992)C(R993)C(R994)C(R995)C(R996)C(R997)C(R998)C(R999)C(R1000)C(R1001)C(R1002)C(R1003)C(R1004)C(R1005)C(R1006)C(R1007)C(R1008)C(R1009)C(R1010)C(R1011)C(R1012)C(R1013)C(R1014)C(R1015)C(R1016)C(R1017)C(R1018)C(R1019)C(R1020)C(R1021)C(R1022)C(R1023)C(R1024)C(R1025)C(R1026)C(R1027)C(R1028)C(R1029)C(R1030)C(R1031)C(R1032)C(R1033)C(R1034)C(R1035)C(R1036)C(R1037)C(R1038)C(R1039)C(R1040)C(R1041)C(R1042)C(R1043)C(R1044)C(R1045)C(R1046)C(R1047)C(R1048)C(R1049)C(R1050)C(R1051)C(R1052)C(R1053)C(R1054)C(R1055)C(R1056)C(R1057)C(R1058)C(R1059)C(R1060)C(R1061)C(R1062)C(R1063)C(R1064)C(R1065)C(R1066)C(R1067)C(R1068)C(R1069)C(R1070)C(R1071)C(R1072)C(R1073)C(R1074)C(R1075)C(R1076)C(R1077)C(R1078)C(R1079)C(R1080)C(R1081)C(R1082)C(R1083)C(R1084)C(R1085)C(R1086)C(R1087)C(R1088)C(R1089)C(R1090)C(R1091)C(R1092)C(R1093)C(R1094)C(R1095)C(R1096)C(R1097)C(R1098)C(R1099)C(R1100)C(R1101)C(R1102)C(R1103)C(R1104)C(R1105)C(R1106)C(R1107)C(R1108)C(R1109)C(R1110)C(R1111)C(R1112)C(R1113)C(R1114)C(R1115)C(R1116)C(R1117)C(R1118)C(R1119)C(R1120)C(R1121)C(R1122)C(R1123)C(R1124)C(R1125)C(R1126)C(R1127)C(R1128)C(R1129)C(R1130)C(R1131)C(R1132)C(R1133)C(R1134)C(R1135)C(R1136)C(R1137)C(R1138)C(R1139)C(R1140)C(R1141)C(R1142)C(R1143)C(R1144)C(R1145)C(R1146)C(R1147)C(R1148)C(R1149)C(R1150)C(R1151)C(R1152)C(R1153)C(R1154)C(R1155)C(R1156)C(R1157)C(R1158)C(R1159)C(R1160)C(R1161)C(R1162)C(R1163)C(R1164)C(R1165)C(R1166)C(R1167)C(R1168)C(R1169)C(R1170)C(R1171)C(R1172)C(R1173)C(R1174)C(R1175)C(R1176)C(R1177)C(R1178)C(R1179)C(R1180)C(R1181)C(R1182)C(R1183)C(R1184)C(R1185)C(R1186)C(R1187)C(R1188)C(R1189)C(R1190)C(R1191)C(R1192)C(R1193)C(R1194)C(R1195)C(R1196)C(R1197)C(R1198)C(R1199)C(R1200)C(R1201)C(R1202)C(R1203)C(R1204)C(R1205)C(R1206)C(R1207)C(R1208)C(R1209)C(R1210)C(R1211)C(R1212)C(R1213)C(R1214)C(R1215)C(R1216)C(R1217)C(R1218)C(R1219)C(R1220)C(R1221)C(R1222)C(R1223)C(R1224)C(R1225)C(R1226)C(R1227)C(R1228)C(R1229)C(R1230)C(R1231)C(R1232)C(R1233)C(R1234)C(R1235)C(R1236)C(R1237)C(R1238)C(R1239)C(R1240)C(R1241)C(R1242)C(R1243)C(R1244)C(R1245)C(R1246)C(R1247)C(R1248)C(R1249)C(R1250)C(R1251)C(R1252)C(R1253)C(R1254)C(R1255)C(R1256)C(R1257)C(R1258)C(R1259)C(R1260)C(R1261)C(R1262)C(R1263)C(R1264)C(R1265)C(R1266)C(R1267)C(R1268)C(R1269)C(R1270)C(R1271)C(R1272)C(R1273)C(R1274)C(R1275)C(R1276)C(R1277)C(R1278)C(R1279)C(R1280)C(R1281)C(R1282)C(R1283)C(R1284)C(R1285)C(R1286)C(R1287)C(R1288)C(R1289)C(R1290)C(R1291)C(R1292)C(R1293)C(R1294)C(R1295)C(R1296)C(R1297)C(R1298)C(R1299)C(R1300)C(R1301)C(R1302)C(R1303)C(R1304)C(R1305)C(R1306)C(R1307)C(R1308)C(R1309)C(R1310)C(R1311)C(R1312)C(R1313)C(R1314)C(R1315)C(R1316)C(R1317)C(R1318)C(R1319)C(R1320)C(R1321)C(R1322)C(R1323)C(R1324)C(R1325)C(R1326)C(R1327)C(R1328)C(R1329)C(R1330)C(R1331)C(R1332)C(R1333)C(R1334)C(R1335)C(R1336)C(R1337)C(R1338)C(R1339)C(R1340)C(R1341)C(R1342)C(R1343)C(R1344)C(R1345)C(R1346)C(R1347)C(R1348)C(R1349)C(R1350)C(R1351)C(R1352)C(R1353)C(R1354)C(R1355)C(R1356)C(R1357)C(R1358)C(R1359)C(R1360)C(R1361)C(R1362)C(R1363)C(R1364)C(R1365)C(R1366)C(R1367)C(R1368)C(R1369)C(R1370)C(R1371)C(R1372)C(R1373)C(R1374)C(R1375)C(R1376)C(R1377)C(R1378)C(R1379)C(R1380)C(R1381)C(R1382)C(R1383)C(R1384)C(R1385)C(R1386)C(R1387)C(R1388)C(R1389)C(R1390)C(R1391)C(R1392)C(R1393)C(R1394)C(R1395)C(R1396)C(R1397)C(R1398)C(R1399)C(R1400)C(R1401)C(R1402)C(R1403)C(R1404)C(R1405)C(R1406)C(R1407)C(R1408)C(R1409)C(R1410)C(R1411)C(R1412)C(R1413)C(R1414)C(R1415)C(R1416)C(R1417)C(R1418)C(R1419)C(R1420)C(R1421)C(R1422)C(R1423)C(R1424)C(R1425)C(R1426)C(R1427)C(R1428)C(R1429)C(R1430)C(R1431)C(R1432)C(R1433)C(R1434)C(R1435)C(R1436)C(R1437)C(R1438)C(R1439)C(R1440)C(R144

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry.



RN 183563-92-6 CAPLUS

OH Propanamide, 2-amino-N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]2-methylpropyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-3-(methylsulfonyl)-, monohydrochloride, (2R)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 183563-93-7 CAPLUS

OH Propanamide, 2-amino-N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]2-methylpropyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-3-(methylsulfonyl)-, monohydrochloride, (2R)- (9C1) (CA INDEX NAME)

Absolute stereochemistry

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996-60725 CAPLUS

DOCUMENT NUMBER: 125-32802

TITLE: Preparation of N-[(1S,2R)-3-[(1,3-benzodioxol-5-yl)sulfonyl]2-methylpropyl]amino)-2-hydroxy-1-(phenylmethyl)propyl]-3-(methylsulfonyl)-, monohydrochloride, (2R)- (9C1) (CA INDEX NAME)

INVENTOR(S): Getman, Daniel P.; Orescoseno, Gary A.; Freskas, John N.; Naqvi, Michael L.; Sikorski, James A.; Devadas, Balakrishnan; Nagarajan, Srinivasan; McDowall, Joseph J.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: JCT Inc., Appl. - 173 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO. F.I.N.O. DATE APPLICATION NO. DATE

WO 9628418 A1 19960219 WO 1996-05262 19960307

W. AL, AM, AT, AU, AZ, BR, BG, BF, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KR, KG, KP, KR, KZ, UK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, NE, NO, NL, PL, PT, RO, RU, SD, SE, SG, SI

RK, RE, LS, MG, SO, ST, US, UT, BF, CH, DK, DE, ES, FI, FR, GB, GR, HE, IT, LI, LU, MC, ME, PT, SE, SI, SK, ST, TR, UA, UK, US, YU

US 5705560 A 19980106 US 1995-47825 19950607

AU 966993 A3 19960202 AU 1996-66961 19960307

AU 711098 B2 19951007

EP 813519 A1 19971229 EP 1996-11229 19960307

EP 813519 B1 20010609

R, AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI

BR 960740 A 19960300 BR 1996-7490 19960307

JP 1153044 T2 19990326 JP 1996-62766 19960307

AT 201014 F 20010615 AT 1996-01229 19960307

NO 970146 A 19971116 NO 1997-4346 19970909

US 595870 A 19991116 US 1997-91229 19970307

US 6380180 B1 20009430 US 2000-67449 20000529

US 1996-401838 A2 19960310

US 1996-478625 A2 19960407

US 1996-05262 W 19960307


US 1997-91229 A1 19971210

US 1999-411374 A1 19991004


PRIORITY APPL. INFO.: WPPAT 125-32802

OTHER SOURCE(S): GENPAC SOURCE(S):

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



ABSTRACT:

ABSTRACT: NSC(=O)CNC1CNC2CNC3CNC4CNC5C6C7C8C9C10C11C12C13C14C15C16C17C18C19C20C21C22C23C24C25C26C27C28C29C30C31C32C33C34C35C36C37C38C39C40C41C42C43C44C45C46C47C48C49C50C51C52C53C54C55C56C57C58C59C60C61C62C63C64C65C66C67C68C69C70C71C72C73C74C75C76C77C78C79C80C81C82C83C84C85C86C87C88C89C90C91C92C93C94C95C96C97C98C99C100C101C102C103C104C105C106C107C108C109C110C111C112C113C114C115C116C117C118C119C120C121C122C123C124C125C126C127C128C129C130C131C132C133C134C135C136C137C138C139C140C141C142C143C144C145C146C147C148C149C150C151C152C153C154C155C156C157C158C159C160C161C162C163C164C165C166C167C168C169C170C171C172C173C174C175C176C177C178C179C180C181C182C183C184C185C186C187C188C189C190C191C192C193C194C195C196C197C198C199C200C201C202C203C204C205C206C207C208C209C210C211C212C213C214C215C216C217C218C219C220C221C222C223C224C225C226C227C228C229C230C231C232C233C234C235C236C237C238C239C240C241C242C243C244C245C246C247C248C249C250C251C252C253C254C255C256C257C258C259C260C261C262C263C264C265C266C267C268C269C270C271C272C273C274C275C276C277C278C279C280C281C282C283C284C285C286C287C288C289C290C291C292C293C294C295C296C297C298C299C300C301C302C303C304C305C306C307C308C309C310C311C312C313C314C315C316C317C318C319C320C321C322C323C324C325C326C327C328C329C330C331C332C333C334C335C336C337C338C339C340C341C342C343C344C345C346C347C348C349C350C351C352C353C354C355C356C357C358C359C360C361C362C363C364C365C366C367C368C369C370C371C372C373C374C375C376C377C378C379C380C381C382C383C384C385C386C387C388C389C390C391C392C393C394C395C396C397C398C399C400C401C402C403C404C405C406C407C408C409C410C411C412C413C414C415C416C417C418C419C420C421C422C423C424C425C426C427C428C429C430C431C432C433C434C435C436C437C438C439C440C441C442C443C444C445C446C447C448C449C450C451C452C453C454C455C456C457C458C459C460C461C462C463C464C465C466C467C468C469C470C471C472C473C474C475C476C477C478C479C480C481C482C483C484C485C486C487C488C489C490C491C492C493C494C495C496C497C498C499C500C501C502C503C504C505C506C507C508C509C510C511C512C513C514C515C516C517C518C519C520C521C522C523C524C525C526C527C528C529C530C531C532C533C534C535C536C537C538C539C540C541C542C543C544C545C546C547C548C549C550C551C552C553C554C555C556C557C558C559C560C561C562C563C564C565C566C567C568C569C570C571C572C573C574C575C576C577C578C579C580C581C582C583C584C585C586C587C588C589C590C591C592C593C594C595C596C597C598C599C600C601C602C603C604C605C606C607C608C609C610C611C612C613C614C615C616C617C618C619C620C621C622C623C624C625C626C627C628C629C630C631C632C633C634C635C636C637C638C639C640C641C642C643C644C645C646C647C648C649C650C651C652C653C654C655C656C657C658C659C660C661C662C663C664C665C666C667C668C669C670C671C672C673C674C675C676C677C678C679C680C681C682C683C684C685C686C687C688C689C690C691C692C693C694C695C696C697C698C699C700C701C702C703C704C705C706C707C708C709C710C711C712C713C714C715C716C717C718C719C720C721C722C723C724C725C726C727C728C729C730C731C732C733C734C735C736C737C738C739C740C741C742C743C744C745C746C747C748C749C750C751C752C753C754C755C756C757C758C759C760C761C762C763C764C765C766C767C768C769C770C771C772C773C774C775C776C777C778C779C780C781C782C783C784C785C786C787C788C789C790C791C792C793C794C795C796C797C798C799C800C801C802C803C804C805C806C807C808C809C810C811C812C813C814C815C816C817C818C819C820C821C822C823C824C825C826C827C828C829C830C831C832C833C834C835C836C837C838C839C840C841C842C843C844C845C846C847C848C849C850C851C852C853C854C855C856C857C858C859C860C861C862C863C864C865C866C867C868C869C870C871C872C873C874C875C876C877C878C879C880C881C882C883C884C885C886C887C888C889C890C891C892C893C894C895C896C897C898C899C900C901C902C903C904C905C906C907C908C909C910C911C912C913C914C915C916C917C918C919C920C921C922C923C924C925C926C927C928C929C930C931C932C933C934C935C936C937C938C939C940C941C942C943C944C945C946C947C948C949C950C951C952C953C954C955C956C957C958C959C960C961C962C963C964C965C966C967C968C969C970C971C972C973C974C975C976C977C978C979C980C981C982C983C984C985C986C987C988C989C990C991C992C993C994C995C996C997C998C999C1000C1001C1002C1003C1004C1005C1006C1007C1008C1009C1010C1011C1012C1013C1014C1015C1016C1017C1018C1019C1020C1021C1022C1023C1024C1025C1026C1027C1028C1029C1030C1031C1032C1033C1034C1035C1036C1037C1038C1039C1040C1041C1042C1043C1044C1045C1046C1047C1048C1049C1050C1051C1052C1053C1054C1055C1056C1057C1058C1059C1060C1061C1062C1063C1064C1065C1066C1067C1068C1069C1070C1071C1072C1073C1074C1075C1076C1077C1078C1079C1080C1081C1082C1083C1084C1085C1086C1087C1088C1089C1090C1091C1092C1093C1094C1095C1096C1097C1098C1099C1100C1101C1102C1103C1104C1105C1106C1107C1108C1109C1110C1111C1112C1113C1114C1115C1116C1117C1118C1119C1120C1121C1122C1123C1124C1125C1126C1127C1128C1129C1130C1131C1132C1133C1134C1135C1136C1137C1138C1139C1140C1141C1142C1143C1144C1145C1146C1147C1148C1149C1150C1151C1152C1153C1154C1155C1156C1157C1158C1159C1160C1161C1162C1163C1164C1165C1166C1167C1168C1169C1170C1171C1172C1173C1174C1175C1176C1177C1178C1179C1180C1181C1182C1183C1184C1185C1186C1187C1188C1189C1190C1191C1192C1193C1194C1195C1196C1197C1198C1199C1200C1201C1202C1203C1204C1205C1206C1207C1208C1209C1210C1211C1212C1213C1214C1215C1216C1217C1218C1219C1220C1221C1222C1223C1224C1225C1226C1227C1228C1229C1230C1231C1232C1233C1234C1235C1236C1237C1238C1239C1240C1241C1242C1243C1244C1245C1246C1247C1248C1249C1250C1251C1252C1253C1254C1255C1256C1257C1258C1259C1260C1261C1262C1263C1264C1265C1266C1267C1268C1269C1270C1271C1272C1273C1274C1275C1276C1277C1278C1279C1280C1281C1282C1283C1284C1285C1286C1287C1288C1289C1290C1291C1292C1293C1294C1295C1296C1297C1298C1299C1300C1301C1302C1303C1304C1305C1306C1307C1308C1309C1310C1311C1312C1313C1314C1315C1316C1317C1318C1319C1320C1321C1322C1323C1324C1325C1326C1327C1328C1329C1330C1331C1332C1333C1334C1335C1336C1337C1338C1339C1340C1341C1342C1343C1344C1345C1346C1347C1348C1349C1350C1351C1352C1353C1354C1355C1356C1357C1358C1359C1360C1361C1362C1363C1364C1365C1366C1367C1368C1369C1370C1371C1372C1373C1374C1375C1376C1377C1378C1379C1380C1381C1382C1383C1384C1385C1386C1387C1388C1389C1390C1391C1392C1393C1394C1395C1396C1397C1398C1399C1400C1401C1402C1403C1404C1405C1406C1407C1408C1409C1410C1411C1412C1413C1414C1415C1416C1417C1418C1419C1420C1421C1422C1423C1424C1425C1426C1427C1428C1429C1430C1431C1432C1433C1434C1435C1436C1437C1438C1439C1440C1441C1442C1443C1444C1445C1446C1447C1448C1449C1450C1451C1452C1453C1454C1455C1456C1457C1458C1459C1460C1461C1462C1463C1464C1465C1466C1467C1468C1469C1470C1471C1472C1473C1474C1475C1476C1477C1478C1479C1480C1481C1482C1483C1484C1485C1486C1487C1488C1489C1490C1491C1492C1493C1494C1495C1496C1497C1498C1499C1500C1501C1502C1503C1504C1505C1506C1507C1508C1509C1510C1511C1512C1513C1514C1515C1516C1517C1518C1519C1520C1521C1522C1523C1524C1525C1526C1527C1528C1529C1530C1531C1532C1533C1534C1535C1536C1537C1538C1539C1540C1541C1542C1543C1544C1545C1546C1547C1548C1549C1550C1551C1552C1553C1554C1555C1556C1557C1558C1559C1560C1561C1562C1563C1564C1565C1566C1567C1568C1569C1570C1571C1572C1573C1574C1575C1576C1577C1578C1579C1580C1581C1582C1583C1584C1585C1586C1587C1588C1589C1590C1591C1592C1593C1594C1595C1596C1597C1598C1599C1600C1601C1602C1603C1604C1605C1606C1607C1608C1609C1610C1611C1612C1613C1614C1615C1616C1617C1618C1619C1620C1621C1622C1623C1624C1625C1626C1627C1628C1629C1630C1631C1632C1633C1634C1635C1636C1637C1638C1639C1640C1641C1642C1643C1644C1645C1646C1647C1648C1649C1650C1651C1652C1653C1654C1655C1656C1657C1658C1659C1660C1661C1662C1663C1664C1665C1666C1667C1668C1669C1670C1671C1672C1673C1674C1675C1676C1677C1678C1679C1680C1681C1682C1683C1684C1685C1686C1687C1688C1689C1690C1691C1692C1693C1694C1695C1696C1697C1698C1699C1700C1701C1702C1703C1704C1705C1706C1707C1708C1709C1710C1711C1712C1713C1714C1715C1716C1717C1718C1719C1720C1721C1722C1723C1724C1725C1726C1727C1728C1729C1730C1731C1732C1733C1734C1735C1736C1737C1738C1739C1740C1741C1742C1743C1744C1745C1746C1747C1748C1749C1750C1751C1752C1753C1754C1755C1756C1757C1758C1759C1760C1761C1762C1763C1764C1765C1766C1767C1768C1769C1770C1771C1772C1773C1774C1775C1776C1777C1778C1779C1780C1781C1782C1783C1784C1785C1786C1787C1788C1789C1790C1791C1792C1793C1794C1795C1796C1797C1798C1799C1800C1801C1802C1803C1804C1805C1806C1807C1808C1809C1810C1811C1812C1813C1814C1815C1816C1817C1818C1819C1820C1821C1822C1823C1824C1825C1826C1827C1828C1829C1830C1831C1832C1833C1834C1835C1836C1837C1838C1839C1840C1841C1842C1843C1844C1845C1846C1847C1848C1849C1850C1851C1852C1853C1854C1855C1856C1857C1858C1859C1860C1861C1862C1863C1864C1865C1866C1867C1868C1869C1870C1871C1872C1873C1874C1875C1876C1877C1878C1879C1880C1881C1882C1883C1884C1885C1886C1887C1888C1889C1890C1891C1892C1893C1894C1895C1896C1897C1898C1899C1900C1901C1902C1903C1904C1905C1906C1907C1908C1909C1910C1911C1912C1913C1914C1915C1916C1917C1918C1919C1920C1921C1922C1923C1924C1925C1926C1927C1928C1929C1930C1931C1932C1933C1934C1935C1936C1937C1938C1939C1940C1941C1942C1943C1944C1945C1946C1947C1948C1949C1950C1951C195


L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 183004-73-1 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(16-benzothiazolyl)sulfonyl]1(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183004-74-2 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl]1(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(8R-methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183004-75-3 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl]1(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 183182-29-8 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl]1(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(1S-methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 183004-99-1P 183005-01-8P

RL RCT (Reactant); SPH (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prodn. of N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl]1(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(1S-methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

RN 183004-99-1 CAPLUS

CN (E)-ethene-1,2-diol, 5-[(2S)-3-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl]1(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(1S-methylsulfonyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183005-01-8 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl]1(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(1S-methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 183004-76-4 CAPLUS

CN Carbenic acid, 1S-[[[(1R,3S)-2-hydroxy-3-[(2S)-2-methyl-3-(methylsulfonyl)-1-oxopropyl]amino]-4-phenylbutyl]1(2-methylpropyl)amino]sulfonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183004-77-5 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl]1(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183004-78-6 CAPLUS

CN Propenamide, N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl]1(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)

Chemical structure of Propenamide 25: N-[(1S,2R)-3-[(11,3-benzodioxol-5-ylsulfonyl]1(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl-3-(1S-methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1996-153437 CAPLUS
 DOCUMENT NUMBER: 124-220480
 TITLE: Retroviral protease inhibitor combinations
 INVENTOR(S): Bryant, Martin L.; Reiss, Karen E.; Sauter, Mary;
 Tucker, Simon P.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEX: PI4302
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY REC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533464	A2	19951214	MO 1995-056673	19950602
WO 9533464	A2	19960104		
V. AM. AT. AU. BB. BG. BR. BY. CA. CH. CN. CZ. DE. DK. EE. ES. FI.				
GB. GR. HU. IL. JP. IE. KG. KP. KR. KZ. LA. LR. LT. LU. LV. MD.				
MG. MW. MY. NZ. NO. NZ. PL. PT. RO. RU. SD. SE. SI. SK. TJ.				
TM. TT				
RU: KE. KM. SD. SZ. UG. AT. BE. CH. DE. DK. ES. FR. GB. GR. IE. IT.				
LU. MC. ML. PT. SE. BF. BJ. CF. CG. CI. CM. GA. GN. HE. NE. NE.				
SA. TD. TG				
CA 2191948	AA	19951214	CA 1995-281948	19950602
AU 9526510	A1	19960104	AU 1995-26610	19950602
AU 686299	BE	19960903		
EP 762880	A1	19970319	EP 1995-921428	19950602
F. AT. BE. CH. DE. ES. FR. GB. GR. IE. IT. LI. LU. NL. PT. SE				
BR 9507912	A	19970812	BR 1995-7912	19960602
CN 1166766	A	19971203	CN 1995-18444	19950602
HU 75975	A2	19960104	HU 1995-3269	19960602
JP 1050324	T2	19960626	JP 1995-501057	19950602
US 6180277	A	20000608	US 1995-026154	19950602
PL 188079	B1	20001229	PL 1995-317425	19960602
NO 2166317	C2	20010610	NO 1997-100123	19950602
NO 9606136	A	19970310	NO 1995-5135	19961202
FI 9604335	F1	1996-0535	FI 1996-4535	19961203
PRIORITY APPL. INFO.			US 1994-253628 A2	19940603
			MO 1995-056673	19950602

ABSTRACT:

A method is disclosed for the treatment of mammalian retrovirus infections, e.g. HIV, using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo. In particular, the invention provides protease inhibitor compds. used in combination therapy with other protease inhibitor compds. Also disclosed is combination therapy with a combination of protease inhibitors and antiviral

L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2003 ACS (Continued)
 agents other than protease inhibitors. Prep. and activity of selected inhibitors is included.


IT 174303-66-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPH (Synthetic preparation); THB (Therapeutic use); BTL (Biological study); PREP (Preparation); GCS (Gases)
 (retroviral protease inhibitor combinations, and protease inhibitor prep.)

RU 174303-66-3 CAPLUS

CN Propanamide, 8-((1S,2S)-3-((1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(propylmethylsulfonyl)-2-methyl-3-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

83.32

232.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-11.72

-11.72

STN INTERNATIONAL LOGOFF AT 11:26:20 ON 04 MAR 2003